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7Foreword
The European Monitoring Centre for Drugs and Drug Addiction hereby presents its twelfth 
General report of activities to the European Parliament, the Council of the European 
Union, the European Commission and the Member States, following its adoption by the 
Management Board in May 2007. The report provides an account of the EMCDDA’s 
activities and outputs in 2006, the final year of its fourth three-year work programme 
(2004–2006). It is the second report to be submitted by the Centre since Wolfgang Götz 
took up position as Director, and the extensive list of delivered projects at the end of this 
report suggests that the Centre is in good hands. 
What is striking about this report is the extent to which the EMCDDA has matured over 
the years. The Centre is now showing signs of its full potential and global resonance. 
The 2006 Annual report on the state of the drugs problem in Europe reached more 
people in more countries than ever before. The Centre has now consolidated its position 
as the most reliable — and respected — source of data on illicit drug use across Europe. 
Looking back at the 2004–2006 work programme, the Centre has played a significant 
role in welcoming the new Member States, bringing them quickly up-to-speed on the 
way Europe monitors the drugs phenomenon. Work naturally remains to be done on 
the quality and comparability of our data, and in our analysis we must be continually 
cautious about drawing conclusions that are fully backed up by evidence. But to have 
reached this level in such a short time is a significant achievement.
Throughout 2006, EU institutional cooperation was frequent and productive. The 
EMCDDA continues to elicit strong interest and dialogue at the key event in the EMCDDA 
calendar, the presentation in November of the Annual report to the European Parliament. 
During 2006, the Centre also stressed the importance of maintaining contacts at all 
levels of the EU institutions: with the Commission, in particular DG Justice, Freedom and 
Security and DG Sanco; with the Parliament, especially the Committee on Civil Liberties, 
Justice and Home Affairs; and with the Council. Notable events in 2006 were visits to the 
Centre from President Barroso and Commissioner Frattini. The Centre continues to have 
strong relationships with its sister EU agencies. It had strong contacts with the European 
Centre for Disease Prevention and Control (ECDC) which became operational in 2005, 
and with Europol. I also congratulate the Director for having been nominated coordinator 
of the agencies from March 2008 for one year.
As we close off 2006 with this report, it is important to underline the raison-d’être of the 
Centre, which has never been more strong. Prices of many illicit drugs have dropped in 
Europe. There is evidence of increasingly problematic cocaine and cannabis use. And 
there are polydrug binge patterns which are putting the health of young people at risk. 
Any response to such trends must be well-informed in order to be well-targeted. The 
EMCDDA supplies this information.
In submitting this report, I would like to express my gratitude to our Vice-Chairperson, 
Mr Ralf Löfstedt, my colleagues of the Management Board and its Executive Committee, 
and of the Scientific Committee for their commitment to the objectives of the agency. My 
special thanks go to the staff of the Centre, my personal assistants, and to all members 
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of our Reitox national focal points. All of you are vital to the functioning of the EMCDDA, 
and our proven spirit of positive cooperation is an excellent basis for EMCDDA’s next 
three-year work programme. 
Marcel Reimen 
Chairman of the EMCDDA Management Board
Introduction
In the last EMCDDA report I highlighted that 2005 was very much a year for orientation. 
After taking up my position as Director, I prioritised a smooth transition from my 
predecessor, set strategic objectives, restructured management, planned resources and set 
in motion a number of vital administrative procedures. In short, a roadmap was laid out 
for subsequent years. 
By contrast, 2006 can be seen as a year of road building at the Centre. The Centre’s 
founding regulation was recast in December 2006, broadening the scope of the centre 
in the area of monitoring new trends and polydrug use. New staff were recruited, in 
particular a head of human resources, a new head of one of the scientific units and 
several scientific experts. So at the end of 2006 the Centre was stronger than ever 
before, numbering 87 staff as opposed to 72 in 2005. Substantial effort was made 
to ensure new recruits were welcomed and given the resources they need to become 
productive. Investment was also channelled into new technology, in particular the Fonte 
system for gathering data, and improvements on the EMCDDA website and intranet. On 
the administrative front, 2006 saw a number of innovations, notably in relation to systems 
of staff appraisal and stronger administrative management of contractual relationships 
with the Reitox network. Many of these tasks entailed substantial investment for which the 
benefits will only be reaped in the years to come.
When mentioning such innovations and new recruits, it is easy to lose sight of the overall 
picture of consolidation and continuity. The Centre’s day-to-day activities continued 
apace. It finalised the adaptations following the May 2004 staff regulation reforms. 
And much work involved closing off the projects from the previous three-year work 
programme and validating its successor, the 2007–2009 work programme. The new 
work programme is bold, sets strict targets and assumes strong teamwork and an ability 
to execute projects efficiently.
Quality outputs were produced throughout 2006. The Annual report remains the key 
product by which the Centre’s work and impact is measured by European decision 
makers and citizens. In 2006 it benefited from continued improvement in terms of 
underlying indicators and comparability, with improved coverage in a number of tables, 
in particular among the newer Member States. It also benefited from stronger-than-ever 
positioning and placement, achieving its highest ever visibility in the European media. 
The EMCDDA is increasingly referenced by journalists, analysts and researchers across 
Europe, strengthening the Centre’s claim to being the key reference point on illicit drugs 
in Europe.
During 2006 the Centre also increased cooperation and contacts with its institutional 
partners such as the Commission, Parliament and Council, and worked on a number of 
high profile projects with peer organisations such as Europol, the UNODC, WHO and 
WCO. International relations were also a strong feature of activities, with fruitful contacts 
with the US, Russia and Latin America. In Lisbon, frequent negotiations were held with 
the Portuguese authorities on the Centre’s move to a new building — the Ribeira das 
Naus complex. This time next year I hope to report that that the Centre’s units have been 
re-united in a single premises, sharing facilities with our colleagues at the European 
Maritime Safety Agency.
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While the road has been firmly laid during 2006, challenges and opportunities 
remain. There are statistical challenges involved with the diversity of a Europe 
which now numbers nearly 500 million people. Today the EMCDDA reports on 29 
countries, compared to 16 in 2002. Perhaps because of this diversity, Europe also 
remains somewhat under-represented in the research literature, which tends towards 
anglocentrism. So the EMCDDA has a role to play in collecting and communicating 
European knowledge, best practices and expertise on drugs to an international audience. 
Nonetheless, the Centre must always remain focused on what we do best: monitoring the 
European situation. The latest Annual report published worrying findings about cocaine 
and synthetic drugs use, and this is something that Europe must respond to.
I would like to thank the members of the Management Board for their valued input and 
cooperation. Most of all, I would also like to thank my staff for the commitment they show 
every day in building the Centre’s reputation and expertise. With every year, the body 
of data collected by the Centre becomes richer, and the possibility for identifying and 
measuring long-term trends greater. 
Drugs remain a hot-button issue in Europe, and more than ever there is a need for the 
Centre’s work to enlighten public policy. 
Wolfgang Götz  
Director, EMCDDA
11I
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Chapter 1 
Chapter I: Synthesis of main results compared with 
objectives of 2006 work programme 
The 2006 work programme (1) brought to completion the EMCDDA’s three-year work 
programme (2004–2006). This section provides a summary of the main activities of 
the Centre during the year, organised according to the priorities set in the 2006 work 
programme. Note that a more detailed description of activities by programme area can 
be found in Chapter II.
Priority 1
Continuation/follow up of the 2005 work programme
This priority embraced three main areas:
• Consolidating and implementing the EMCDDA data storage and retrieval system for 
quantitative and qualitative information. Following needs evaluation and specifications 
during 2005, substantial work was carried out in 2006 on Fonte, the EMCDDA’s new 
internet-based system for data collection. Work on Fonte was supplementary to continuing 
updates to the existing EISDD database, in particular placing significant workload on 
the Centre’s Epidemiology, crime and markets (EPI) unit. A system was developed from 
January to August, and was tested with the migration of historical (pre-2006) data in 
the last quarter of 2006. Full migration to Fonte is gradual and scheduled for the period 
2007–2008. Substantial cooperation with the Reitox national focal points will be needed 
throughout the launch period of the application, although initial feedback during 2006 
was encouraging. 
With regard to qualitative information, the Scientific partners and documentation (SCD) 
unit enhanced networking with the European and international scientific research 
community in the area of drugs and addiction, and appointed a new head of the 
Centre’s documentation centre. The EMCDDA continued to focus on aggregating research 
in electronic form, subscribing to the main electronic journals services, exploring new 
methods for managing references and citations, and enhancing its literature search 
service. An electronic library service was conceptualised during the year, and recruitment 
was launched for a new research information manager, expected to start during 2007.
• Executing EMCDDA core tasks essential to implementing, developing and maintaining 
the existing instruments and mechanisms for data collection and analysis of the drug 
phenomenon. In what has become a routine process of continuous improvement, the 
EMCDDA’s key indicators continued to be refined across-the-board in 2006. Notable 
work took place in 2006 in several areas relating to core indicators and data collection: 
stimulant trends; trends in intensive cannabis use; testing of the new ESPAD (school 
survey) instruments; club surveys; improving the sensitivity of the problematic drug use 
indicator to include non-opiate drug use and polydrug use problems; drugs in waste 
water; drug treatment reporting; total mortality; risk behaviour; supply-side data; and 
drug prices. 
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(1) http://www.emcdda.europa.eu/index.cfm?nnodeid=24698
Tasks in the area of interventions, laws and strategies were likewise subject to 
enhancement. These included: modifications to structured questionnaires and a focus on 
best practice and efficacy evaluation in prevention, in particular work on improving the 
EDDRA database and the Prevention and Evaluation Resources Kit (PERK); environmental 
strategies; drug-related public expenditure; the legal analysis of the legal status of 
drugs testing and substitution treatment. The Communication unit also invested in media 
monitoring, collaborating in particular with the Joint Research Centre’s EMM project 
to harvest media information on drugs. The Centre is now confidently able to monitor 
news on drugs as-and-when it breaks across Europe, with news monitoring in particular 
enriching the EMCDDA’s objective statistical data with stories on a personal, human 
scale.
Particular attention was given in 2006 to fully incorporating the two acceding countries 
which became Member States in January 2007 (Bulgaria and Romania) and the 
candidate countries Turkey and Croatia. This included finalising agreements for Bulgaria 
and Romania’s participation in the work of the EMCDDA, together with implementation 
of two specific projects for technical assistance, under two (Phare) multi-beneficiary 
programmes, one directed at Bulgaria and Romania and the other at Croatia and Turkey.
• Improving EMCDDA data reporting and dissemination on the drug phenomenon. The 
Annual report package remains the key vehicle for reporting on the drugs phenomenon 
in Europe. In 2006 the Annual report was published in 22 languages and comprised the 
Annual report, graphical country data profiles, Statistical bulletin and Selected issues. 
During 2006 it benefited in particular from stronger-than-ever positioning and media 
impact, following improvements to the launch and distribution process. The three Selected 
issues in 2006 were as follows: European drug policies: extended beyond illicit drugs?; 
A gender perspective on drug use and responding to drug problems and Developments in 
drug use within recreational settings. 
Progressing from earlier work in the area in 2005, improvements were made in 2006 on 
the publication of the online Statistical bulletin. Emphasis was placed on the graphical 
display of data on the website and ensuring direct, clickable links between the Annual 
report and the underlying data sources and statistical tables. The Annual report in 2006 
was thus more ‘inter-connected’ and ‘transparent’ than ever, opening up the Centre’s data 
to external statistical research and analysis. 
The EMCDDA public website remains the predominant channel for dissemination of the 
Centre’s information. The Centre’s quarterly newsletter Drugnet Europe also continues 
to keep the Centre’s stakeholders informed of activities and events on a frequent 
basis. The website received around 7,000 unique visits per day in 2006. A notable 
development on the website in 2006 was emphasis on short, structured information of 
an encyclopaedic nature. For example, the format of the website’s Country situation 
summaries was redesigned, providing concise overviews (5–6 pages) of the drug 
situation in 37 countries (25 Member States and Norway, plus 11 Eastern European and 
Balkan countries). Drugs profiles of the main illicit drugs were also developed during 
2006, presenting key facts about drugs in a concise, scientifically-sound format. Thus 
at the end of the year, the website was better able to cater both for the Centre’s core 
audiences who seek detailed information — e.g. Reitox National reports (100 pages), 
monographs, scientific reports and the Annual report — and generalists who seek brief, 
basic information on drugs. 
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Nonetheless, work remains to be done on improving the website, and initial concepts 
were developed in 2006 for improving the thematic structure of the website — by 
substance, by country, by drug discipline such as ‘prevention’ or ‘enforcement’ etc.— and 
for providing access to bibliographic information on EU research and grey literature in 
the drugs field.
Priority 2: Implementing specific activities/tasks required during 2006
This priority covered three areas in 2006.
• Work related to the EU drugs strategy (2005–2012) and Action plan on drugs (2005–
2008). The Centre continues to supply the data to inform the current EU drugs strategy, 
which focuses on tackling drug problems in Europe on both the supply and demand 
side. In this respect, the EMCDDA cooperates strongly with its institutional partners at the 
Commission, Council and Parliament, and with other key EU and international actors such 
as Europol, Eurojust, EuroHIV, Interpol, the Pompidou Group, the UNODC and the WHO. 
At the level of reporting countries, the Reitox national focal points continue to supply 
quantitative and qualitative data that enable national situations, laws and drug policies 
to be monitored and analysed at an international level. In particular during 2006, 
the Selected issue European drug policies: extended beyond illicit drugs? analysed a 
widening in scope in national drug policies to cover both licit as well as illicit substances. 
During 2006 the Centre provided nine thematic papers and further direct input to the 
first European Commission Progress review of the EU action plan on drugs. These papers 
underscored the methodological approach to be used in the final impact evaluation of 
the three-year action plan, planned for 2008. The Centre’s day-to-day work continued 
to mesh with specific objectives in the action plan: improvements in the annual reporting 
exercise (objective 40); trends analysis, in particular via E-POD and Selected issues 
(objective 41); work with the candidate countries Croatia and Turkey, together with 
external contacts with other countries, for example Russia (objective 32); assessment of 
the current state of implementation of the five key epidemiological indicators (objective 
39); testing new ESPAD (school survey) instruments and analysing risk perception of drug 
use in young people (objective 7); improvements to the TDI indicator and prevention 
standard tables (objective 9); coverage of early intervention programmes, risk factors and 
first service uptake (objective 10); analysis of treatment and rehabilitation programmes 
(objective 11, also objectives 12 and 13.2); expansion of the drug-related death 
indicator and analysis of the health impact of drugs (objective 14); monitoring of drug-
related infectious diseases and services (objectives 15, 16, 17), in particular HIV in 
low-prevalence countries (objective 16, and objective 43.2); initial work in the area of 
estimating public expenditure on drugs (objective 42); studies in the area of drug-related 
crime (objective 25).
• The Council Decision on the information exchange, risk assessment and control of 
new psychoactive substances. 2006 was the second implementation year of the Council 
Decision, and during the year the monitoring mechanism for new psychoactive substances 
demonstrated high sensitivity and detection capacity. Seven new psychoactive substances 
were officially notified for the first time during 2006. In particular, the EMCDDA and 
Europol implemented active monitoring of the new psychoactive substance mCPP. Later in 
the year, a project was launched to report about BZP, for submission in February 2007. 
15
Chapter 1 
During 2006 the EMCDDA, in partnership with Europol and the European Medicines 
Agency (EMEA), put in place monitoring tools for a joint information exchange/early 
warning system, for which new Operating guidelines were prepared, tested and 
implemented. Furthermore, in anticipation of the first risk assessment procedure under 
this legal instrument, the Centre launched a revision of its Guidelines for the risk 
assessment of new synthetic drugs. 2006 also saw the first results of the Centre’s E-POD 
methodological tool for the early detection of emerging trends, including a first E-POD 
publication on hallucinogenic mushrooms.
• The recast of the EMCDDA founding regulation, expanding the EMCDDA’s area of 
intervention to cover new methods of drug use, especially polydrug use. During 2006, 
the Centre prepared for the revision, or ‘recast’ of its founding regulation. Work on the 
recast in 2006 included an analysis of the implications of the recast of the EMCDDA 
regulation and of potential risk factors likely to influence its implementation. The revised 
regulation, which updates and replaced the one founding the agency in 1993, was 
signed on 12 December 2006 following a co-decision procedure and entered into force 
on 16 January 2007.
The new document specifically allows the agency to collect, register and analyse 
information on ‘emerging trends in polydrug use’ — that is, the simultaneous use of more 
than one drug, including the combined use of licit and illicit psychoactive substances. 
Other impacts on the work of the Centre include: more focus on providing information 
on best practice in the EU Member States; closer cooperation with the law enforcement 
body, Europol; scope for transfer of the Centre’s know-how to certain non-EU countries 
such as official candidates for EU accession and countries in the Western Balkans; and 
increased clarification of the role to be played by Reitox national focal points. The recast 
also entails changes in the governance of the Centre. The Management Board (on which 
all Member States and other stakeholders are represented) is now assisted by a new six-
member Executive Committee (formerly, the Bureau) to prepare the decisions of the Board 
and to advise the Director. Furthermore, the existing Scientific Committee — currently 
made up of Member States’ nominees — will be slimmed down to a maximum of 15 
members chosen through a public selection process based on scientific excellence and 
independence.
Further tasks during 2006 
In addition to the priorities set by the work programme, 2006 also saw the Centre focus 
on a number of activities that may be considered exceptional compared with most years 
at the Centre.
• Preparations and negotiations with regard to the Centre’s new premises in Lisbon, the 
Ribeira das Naus complex. The Centre has been divided across two offices in different 
areas of Lisbon for several years. There are major efficiencies and benefits to be gained 
by re-uniting staff in a single premises, and the Centre has been keen to do all in its 
power to hasten progress on the proposed Ribeira das Naus complex. The complex 
will jointly house the EMCDDA, the European Maritime Safety Agency (EMSA) and 
the Jacques Delors European Information Centre. The project saw significant progress 
during 2006. Political, technical and security steering meetings were held between the 
General report of activities 2006
16
Centre, EMSA and the Portuguese authorities from the middle of the year. In particular, 
the negotiations required substantial input from the Centre’s Director, administrative and 
legal staff. Construction works began in September 2006 and the complete architectural 
design was approved in November by the Lisbon City Hall. The completion of the project 
is foreseen for the end of 2007 under the Portuguese Presidency of the EU.
• Recruitment procedures to hire staff in priority areas. At the end of 2006, the Centre’s 
workforce was larger than ever before, numbering 87 staff as opposed to 72 in 2005. 
This increase in headcount reflected a basic need to manage the workload entailed 
by EU enlargement (the Annual report now analyses 29 countries, compared to 16 in 
2002). It also took into account the increased scope in the Centre’s activities in the 
context of the recast of the Centre’s founding regulation. Recruitment was highly targeted, 
focusing on building skills in key disciplines: for example, an expert in the economic 
analysis of government expenditure, a new head of documentation and a head of 
the human resources sector. Recruitment also prioritised improving the administrative 
support of experts and Heads of unit, in particular to free up time among senior staff for 
analytical, managerial and production tasks.
Summary
The EMCDDA’s activities during the year broadly reflected the priorities agreed in the 
2006 work programme. This report therefore focuses predominantly on ‘business as 
usual’ tasks to bring to a close the 2004–2006 three-year work programme. The Centre 
continues to benefit from strong cooperation with external stakeholders that amplify the 
impact of the Centre. The Centre’s premises in Lisbon were as usual host to a frequent 
cycle of meetings with experts from across Europe and beyond, reflecting its role as a 
hub for EU drugs expertise. As in previous years, the Annual report can be considered 
the key product of the Centre, uniting all parts of the agency and representing the many 
thousands of underlying daily tasks required to monitor the European drugs situation. 
Nonetheless, 2006 also saw the Centre focus on several specific tasks that will have a 
substantial impact on the Centre’s activities in the mid- to long-term. Some of these were 
directly associated with the recast of the Centre’s founding regulation and the Council 
Decision on new psychoactive substances. Yet a number of projects worked on during the 
year — in particular the Fonte project, the negotiations ahead of the Centre’s relocation 
to a single premises, and the recruitment of new staff — represented investment in time 
and resources that will only be recuperated after several years.
As the Centre matures and enters its next three-year work programme (2007–2009), 
some opportunities and challenges must be highlighted. This report reveals that the 
Centre now benefits from more visibility than ever before. This is positive, yet also implies 
that expectations from the EMCDDA are higher, and that the number of organisations 
wishing to collaborate with the Centre on drug-related issues has increased. The Centre 
is also increasingly facing the need to update and revisit scientific outputs that were 
produced during the early years of its existence, many of which were developed for a 
smaller EU, or at a time when the available data was not as rich as it is today. While the 
previous three-year programme involved many start-up tasks to address enlargement, the 
next one will be characterised by ways to improve efficiency and to provide navigational 
aids for the large body of data that the Centre and its partners are producing. 
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Chapter 2 
Overview of activities by programme
The scientific coordination mechanism: ‘transversal’ work
Activities and results
Monitoring drugs and drug addiction in Europe requires integrating and analysing 
information and analysis from different disciplines (pharmacological, public health and 
prevention, legislative, law enforcement etc.). At the managerial level the scientific 
work of the Centre is divided into two scientific units, together with a third scientific 
support unit. The Director made encouraging cross-unit — or ‘transversal’ — activities 
an important objective for the scientific teams in 2006. Early in the year the Director 
established a scientific coordination mechanism. Although the coordination mechanism 
is still in its early stages, during 2006 some benefits were already noted, in particular 
in improving communication between different scientific teams and in ensuring activities 
were better integrated.
The coordination mechanism consists of the two scientific Heads of unit and a dedicated 
Scientific officer. During 2006, it provided a platform for strategic discussions around the 
scientific aspects of the drafting of the new three-year Work programme and on setting 
overall priorities for studies and meetings, including the preparation of draft tender 
documents for the 2007 work programme (e.g. the update of a literature review on drugs 
and driving, a study on neuroscience). One of the transversal activities supported by the 
coordination team during 2006 was the process of revising the Centre’s reporting tools, 
the launch of a work programme in the field of drugs and driving, as well as support for 
drafting the Annual report and other publications where input from more than one unit is 
required (e.g. selected issues, data profiles, the Statistical bulletin etc.). The coordination 
team also supported some general activities including the development of drug 
profiles, contributions to the Centre’s newsletter Drugnet Europe and ad hoc technical 
collaborations such as working on a common indicator framework with the WHO and 
on epidemiological tools with the UNODC. The coordination mechanism also played 
an important role in improving the process in which technical contracts were managed, 
ensuring that regular progress reviews were conducted and that any technical problems 
were addressed promptly. 
A priority task for the EMCDDA is to provide technical support to the Commission for its 
work on the EU drugs strategy (2) and EU drugs action plans (3). This support typically 
requires cooperation from different parts of the Centre. During 2006 the EMCDDA 
worked closely with the Drugs Coordination Unit of the European Commission’s DG for 
Justice, Freedom and Security, particularly in tracking the implementation of the EU Action 
plan on drugs (2005–2008). The EMCDDA contributed to the first European Commission 
Progress review of the action plan. Nine different thematic papers were prepared by the 
EMCDDA and used by the Commission to facilitate their assessment of the progress made 
in achieving the A action plan objectives in 2005–2006. Thematic papers provided an 
up-to-date overview of available data sources relevant to the objectives, summarised 
baseline information, and presented a critical analysis of the options for mid-term and 
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(2) http://www.emcdda.europa.eu/index.cfm?nnodeid=6790 
(3) http://www.emcdda.europa.eu/index.cfm?nnodeid=10360
final evaluation in each area. The following action plan objectives were covered: 
‘Methods for early detection of risk factors and early intervention’ (objective 10), ‘Ensure 
the availability of and access to targeted and diversified treatment and rehabilitation 
programmes’ (objective 11), ‘Availability and access to harm reduction services’ 
(objective 15), ‘Prevention of the spread of HIV/AIDS, hepatitis C, other blood borne 
infections and diseases’ (objective 16), ‘Reduction of drug-related deaths’ (objective 17), 
‘Provide the necessary technical and other assistance to the candidate and stabilisation 
and association process countries’ (objective 32), ‘Provide reliable and comparable data 
on the key epidemiological indicators’ (objective 39), ‘Provide reliable information on the 
drug situation’ (objective 40.1), and ‘Develop clear information on emerging trends and 
patterns of drug use and drug markets’ (objective 41.1). In addition, as a direct response 
to the needs of the action plan in 2007, a literature review and study on HIV protective 
factors was launched.
An important transversal activity launched by the EMCDDA in 2006 was the new E-
POD methodological tool for the early detection of emerging trends. Using a case study 
approach, E-POD compliments the epidemiological monitoring of the Centre by providing 
a more sensitive and flexible approach to observing possible important changes in drug 
consumption patterns. These then can be fed back into the Centre’s more systematic 
monitoring system. The E-POD method aims to assess the veracity of accumulated 
information by triangulating information available from a wide range of different sources. 
A first case study — an analysis of available information on hallucinogenic mushrooms 
— was undertaken in 2006. This resulted in June 2006 in the publication of a thematic 
paper titled Hallucinogenic mushrooms: an emerging trend case study (4). 
Drugs and driving was a topic investigated by the EMCDDA in 1999 through a literature 
review on the relation between drug use, impaired driving and traffic accidents (5). 
However no significant work was subsequently undertaken and it was decided that this 
topic needed to be readdressed during the 2006 work programme. An update of the 
1999 literature was contracted and the Centre took part in a joint seminar organised 
with European partners and NIDA to elaborate an international standard protocol for 
research studies on drugs and driving. The EMCDDA also developed greater insight 
into related drug use information in the European Commission four-year research project 
DRUID (Driving under the influence of drugs, alcohol and medicine) . In addition, new 
topic overviews on drugs and driving were published in the ELDD, providing up-to-date 
information on the wide variety of legal mechanisms used to sanction driving under the 
influence of drugs in 22 EU Member States and Norway (6).
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(4) http://www.emcdda.europa.eu/?fuseaction=public.AttachmentDownload&nNodeID=18268 
(5) http://www.emcdda.europa.eu/?fuseaction=public.AttachmentDownload&nNodeID=1430 
(6) http://eldd.emcdda.europa.eu/?fuseaction=public.Content&nnodeid=19034
Epidemiology, crime and markets
Activities and results 
The Epidemiology, crime and markets (EPI) unit is responsible for describing the overall 
drug situation based on social survey, public health and criminal justice data sets. In 
addition, activities conducted by the Centre in support of the Council Decision on new 
psychoactive substances (Council Decision 2005/387/JHA (7)) also fall under the 
responsibility of the unit. The key indicators and core data sets which form the basis for 
quantitative reporting on the drug situation are primarily derived from the analysis of 
quantitative registry-based data sets (8). This means that the principal activities of the unit 
must be sensitive to and reflect the external reporting cycle of national data collection 
efforts. The annual cycle of activities is thus on data processing and analysis between 
November and March, and on technical meetings and developmental activities between 
April and October.
EPI unit 2006: general comments
Improvements in the overall availability of data in Europe, both in terms of the number 
of countries reporting and on the ability of countries to report on more data items, 
has resulted in an increasing workload for the department. Furthermore the additional 
countries reporting mean that production and translation tasks are more complex and 
time-consuming. A key task of the unit is to process, clean and analyse quantitative 
data and to manage qualitative and methodological information. Further streamlining 
and improving the efficiency of data management and analysis tasks was undertaken in 
2006. These tasks were vital to the unit: first, to prepare the way for the introduction of 
Fonte, a new data management system (in development for launch in 2007); second, to 
address the need to process an increasing volume of data in a shorter time period. 
A strategic objective of the unit in 2006 was to continue the development of the 
Statistical bulletin to improve the availability of the quantitative data collected by the 
Centre. This was accomplished successfully and the Statistical bulletin has now become 
established as one of the key products of the EMCDDA. Among the important analytical 
tasks during 2006 were: continuing work to model the concept of problem drug use and 
its measurement; incorporating more sensitivity to polydrug use and the problems caused 
by the combined use of more than one substance. A number of developments are of note 
here: for the first time a separate estimate was given for heroin/opiate use in estimates 
of problem drug use in Europe; analysis was more widely available on non opiate drug-
related deaths; work continued on developing better ways to assess problem cannabis 
use and to better document stimulant-related problems.
Highlights
A significant part of the work of the unit involves collecting and processing data, and 
improving reporting methods and tools. In 2006 the development of the new Fonte data 
management system required considerable preparatory work. Moreover, this work was 
supplementary to ongoing tasks to maintain the existing EISDD database. In order to 
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provide direct input for the first European Commission Progress review of the EU drugs 
action plan and to aid ongoing developmental activities, an assessment was made in 
collaboration with the Reitox unit of the current state of implementation of the five key 
epidemiological indicators.
For each indicator, annual technical meetings were held as well as a number of smaller 
technical collaborations and working groups. Each indicator is supported by a network 
of technical experts who contribute, together with the national focal points, to developing 
reporting methods and tools. During 2006, a number of projects were conducted to 
improve the quality of the reporting tools (guidelines, methodological and analytical 
issues) and some improvement and modifications were made to the standard reporting 
tables. Support was provided where required to Member States to aid reporting, and 
considerable efforts went into data checking, management and analysis to prepare the 
Annual report. A number of small analyses and reports were prepared in response to 
both internal and external ad-hoc requests. 
Key indicator: Prevalence and patterns of use among the general population (population 
surveys)
A mainstay of the Centre’s reporting on the drug situation is data from surveys of the 
general and special populations. This indicator developed strongly in 2006 with a 
number of important new surveys becoming available. Improved estimates of overall 
European drug consumption prevalence were made for different consumption patterns. 
This type of analysis is not only of value in itself but also a basis for other theory-driven 
modelling exercises. 
In 2006 particular emphasis was placed on the analysis of stimulant trends and on 
developments in intensive cannabis use, based on a review of all current European 
reporting instruments and measures. Activities included the development of tools 
for measuring dependence and problems in survey data, particularly in relation to 
problematic cannabis use. This was done in close conjunction with preparatory work 
for a field test to be organised in collaboration with Spanish survey researchers on the 
subject. Close collaboration with the ESPAD (9) group was also maintained, leading to 
a number of joint analyses and EMCDDA support for the field testing of the new ESPAD 
instruments. Review work was also conducted on the EMCDDA database on population 
surveys. In addition to surveys of the general population the EMCDDA continued to 
collect information on other population groups. School survey data from ESPAD, WHO 
and HBSC (10) projects and other national exercises (notably in Spain and the United 
Kingdom) are now an established part of EMCDDA data resources. In 2006, the analysis 
of school survey data formed an important part of many analyses conducted about 
patterns and trends in drug use in Europe. In addition complementary sources included 
internet monitoring and data on club surveys derived from site sampling in dance music 
settings. These data provide a useful window on general trends and new developments 
in drug use in recreational settings and made an important contribution to EMCDDA 
analysis in these areas.
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Key indicator: Problem drug use
The problem drug use indicator (PDU) uses various statistical techniques to generate 
estimates of the scale of problematic drug use in Europe. Work continued in 2006 to 
improve the sensitivity of the indicator to non-opiate drug use and polydrug use problems. 
Close collaboration with the other indicators was necessary and progress was made in 
analysing different components of the overall PDU estimate. Work is currently focused 
on improving the current definition of PDU and the availability and quality of PDU 
prevalence and incidence estimates. This was supported by the formation of a small 
expert network, by a network on incidence estimation and via helpdesk advice using 
an expert consultant. The assessment of the potential of new technologies to estimate 
problem drug use has also been under consideration in 2006. A new project was 
launched to explore new techniques to assess the presence of drugs in waste water.
Beyond the standard table related to the key indicators, a revision of the standard tables 
aiming at collecting information on arrests and reports of drug-related offences (ST 11), 
as well as composition of illicit drugs tablets (ST 15) was launched in 2006. Following an 
expert meeting on data collection and analysis of both sets of data, new guidelines for 
the revised standard tables were drafted and the proposal for changes was presented for 
discussion to the national focal points during the heads of focal points meeting. 
Key indicator: Treatment demand
Work in support of the treatment demand indicator (TDI) continued to focus on improving 
data quality and coverage. In parallel with regular dialogue with European experts, this 
work has resulted in the steady improvement of data quality of the treatment demand 
indicator in recent years. Activities were launched during 2006, and are still ongoing, 
to better estimate the total population in treatment, especially those clients in continuous 
substitution therapy. Similarly, work began on the longer-term assessment of data 
coverage issues. An annual expert meeting took place in September 2006, and was 
attended not only by experts from 28 European countries, but also representatives from 
internal units and a number of interested American and African countries. A major output 
arose from collaboration with the UNODC: a toolkit for establishing a treatment reporting 
system and collecting treatment demand data (11). This product is intended for specialists 
working both within the EU and in third countries. TDI data was also incorporated into a 
number of the outputs of the Centre including thematic papers prepared for the European 
Commission, analysis of gender issues and a chapter in the cannabis monograph.
Key indicator: Drug-related deaths and mortality among drug users
Currently two items have been most developed within the drug-related deaths (DRD) 
indicator: acute drug-related deaths in the population and overall mortality among drug 
users. Yet work commenced in 2006 on an additional estimate of total mortality. This 
information will complement existing components of the problem drug use (PDU) indicator. 
Moreover, analysis in 2006 allowed more specification of different substances within the 
overall reporting, which included specific analysis of methadone-related drug deaths. 
Close coordination with other European and international initiatives was maintained, 
and this was particularly important to ensuring the revision of the Centre’s standard DRD 
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protocol (12) to adjust to new ICD-10 definitions. Methodological work during 2006 also 
included the conceptualisation of new indicators of DRD impact (population rates and 
proportional mortality). Another important development in 2006 was fieldwork in nine EU 
countries to improve reporting of the toxicological analysis of death cases.
Key indicator: Drug-related infectious diseases
Infectious diseases are one of the more serious consequences of drug use, and drug 
injecting in particular. The EMCDDA’s infectious disease indicator systematically monitors 
data on drug-related HIV, HCV and HBV in Europe. Reporting in this area is closely 
coordinated with other relevant public health bodies, including in particular the new 
European Centre for Disease Control and Prevention (ECDC) in Sweden (13). A number 
of important new analytical projects were commenced for this indicator during 2006. 
Among these where two related studies to review the literature on low-prevalence 
countries and protective factors for HIV, and a modelling exercise to explore the 
factors that may account for low prevalence of this virus in some European countries. 
This work was conducted to directly support the EU Action Plan on Drugs. Other new 
developments include the production of a much-needed protocol for data collection for 
studies on risk behaviour, as well as a draft report on laboratory surveillance of the 
hepatitis C virus (HCV). In 2006 the main focus of the more general work on drug-related 
infectious diseases has been on improving current guidelines and data reporting tools, 
consolidating and improving the epidemiological database and improving the analysis of 
the available data. This has resulted in the improvement of reporting tools and a number 
of new analyses that were not feasible in previous years. 
Crime, markets and supply data 
Activities on crime and supply issues were overhauled in 2006. The Annual report placed 
greater emphasis on supply-side data and for the first time a European analysis of drug 
prices was included. Investments were made in improving comparability of data, although 
considerable work is still required. An increase in activities was also seen in relation to 
the work conducted in support of the Council Decision on new psychoactive substances, 
with seven new psychoactive substances officially notified for the first time through the 
early-warning mechanism (see section Action on new drugs, below).
Production of scientific and technical outputs
The 2006 Annual report provided an overview of the epidemiological situation in the 
EU regarding: supply and availability of substances; prevalence and patterns of use; 
estimates of problem drug use; demand for treatment; the extent of drug-related infectious 
diseases and drug-related deaths. Additionally, two Selected issues were drafted, 
with some supplementary contributions from the Interventions, law and policies unit. 
These were: A gender perspective on drug use and responding to drug problem; and 
Developments in drug use within recreational settings. Both selected issues encourage a 
more systematic approach to analysing gender and polydrug use issues in the analysis 
performed by the unit. For instance, both ESPAD and TDI data were used to illustrate 
the two topics. For the selected issue on gender, breakdown analyses by sex were also 
performed using data on infectious diseases and drug-related deaths. 
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The draft of a scientific monograph on cannabis was worked on intensely during the 
year, based on input from EMCDDA staff, the Scientific Committee and external authors. 
Following commentary on the manuscript from an external scientific editor publication 
is foreseen in 2007. Drugs profiles — summative information on cannabis, cocaine and 
crack, MDMA, amphetamine, heroin, together with a glossary — were also worked on 
during 2006 and were published on the EMCDDA website in three different languages 
(English, French, German) in April 2007. The profiles provide a synthetic, scientifically-
sound description of the chemistry, pharmacology, synthesis and precursors of the six 
substances, and offer analysis on their physical form and mode of use. In addition, the 
profiles link to specific parts of the Statistical bulletin for each substance.
Action on new drugs
Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, 
risk assessment and control of new psychoactive substances (14) is in its second 
implementation year. The EMCDDA and Europol, in close collaboration with their 
networks — the Reitox national focal points (NFPs) and Europol National Units (ENUs) 
respectively — played a central role in implementing the mechanism for the rapid 
exchange of information on new psychoactive substances that may pose public health 
and social threats. During the year, seven new psychoactive substances were officially 
notified for the first time through the early warning mechanism.
In 2006, upon a request from the European Commission the EMCDDA and 
Europol implemented active monitoring of the new psychoactive substance 1-(3-
chlorophenyl)piperazine (mCPP). Furthermore, in the last quarter of 2006 the EMCDDA 
and Europol accumulated sufficient evidence about another psychoactive substance, 
piperazine–benzylpiperazine (BZP), to launch information collection for production of 
a Joint Report in accordance with Article 5. In compliance with deadlines stipulated 
by the Decision, it was planned that the resulting Europol–EMCDDA Joint Report on a 
new psychoactive substance: 1-benzylpiperazine (BZP) (15) would be submitted to the 
Council, the Commission and the European Medicines Agency (EMEA) on 23 February 
2007. The proactive response of the early-warning system (EWS) to new challenges 
such as the appearance of various psychoactive chemicals of the piperazine group 
proves its high sensitivity and detection capacity towards the production and subsequent 
appearance of new psychoactive (synthetic) substances on the European drug scene. 
In 2006 the EMCDDA, in partnership with Europol and the European Medicines Agency 
(EMEA), put in place most of the organisational elements and monitoring tools for 
the functioning of the information exchange/early warning system. New Operating 
Guidelines for the early warning system were prepared, tested and implemented in 
2006. Furthermore, in anticipation of the first risk assessment procedure under this legal 
instrument, the EMCDDA in the framework of its Scientific committee launched a revision 
of its Guidelines for the risk assessment of new synthetic drugs so as to adapt them for 
the extended scope of the Council Decision 2005/387/JHA, i.e. to cover both new 
narcotic and psychotropic substances. 
In addition to its core objective, the Decision stimulates the identification, monitoring and 
exchange of information on emerging trends in new uses of existing substances and on 
possible public health-related measures. The EWS should prove a valuable asset in the 
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wider development and implementation of epidemiological methods to detect, track and 
understand emerging drug trends e.g. European Perspectives on Drugs (E-POD). Finally, 
to present factual and objective descriptions of internationally-controlled substances the 
EMCDDA launched a new project — Drugs profiles — aimed at providing users of the 
Centre’s products and the general public with short, clear information on individual 
drugs. 
In implementing its activities related to Council Decision 2005/387/JHA, the EMCDDA 
has maintained close contact and information exchange with the European Commission. 
Also, as requested by the Decision the EMCDDA and Europol reported to the European 
Parliament and the Council and the European Commission on the implementation and 
achievements of the mechanism set up by the Decision.
Cooperation
As outlined above, cooperation is an intrinsic part of the Centre’s activities as a 
monitoring centre. The items below are non-exhaustive, yet are representative of the main 
cooperative activities of the EPI unit during 2006. 
European institutional cooperation:
• In the context of the EU action plan on drugs 2005–2008, the EPI unit contributed to 
the first European Commission Progress Review of the action plan.
• Contribution to the preparatory work of the EUROGLEH report. EUROGLEH aims at the 
preparation of the ’global report on health in the European Union‘. This report will focus 
on shared health data interpretation and recommendations for public health actions to be 
undertaken in the EU.
UNODC cooperation:
• In 2006, the EMCDDA revised a Memorandum of Understanding with the UNODC.
• The Centre provided comment and statistical review of the methodology and approach 
to in the UNODC’s illicit drugs index.
• General data quality improved through regular dialogue with European experts and 
the refinement of guidelines and processes. The main output of the work on data quality 
was the publication of the joint EMCDDA-UNODC toolkit on treatment demand indicators 
and data.
WHO cooperation:
• The unit made a proposal for the adaptation of the key indicator for use by WHO 
states, based on discussions with the WHO during 2005. The EMCDDA submitted to the 
WHO a list of basic and core indicators regarding epidemiology and also responses 
related to drug use, to be included in their online data collection.
• The unit also participated in the framework of the WHO Health Behaviour among 
School Children (HBSC) project.
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Interventions, law and policies
Activities and results
The Interventions, laws and policies (RES) unit monitors responses to the drug problem in 
the EU. In particular, it reports on the measures taken in the EU Member States to curb 
the problem of drugs and drug addiction at individual or group level, and analyses the 
impact of national and Community strategies. 
Routine activities continued throughout 2006: data collection; quality assessment of 
reports from the national focal points; improvements and fine-tuning of data collection 
instruments (in particular, the Fonte project); transversal projects relating to the 
EMCDDA’s key indicators; updates to the databases managed by the RES unit (EU drug 
activities, ELDD, EIB, PERK and EDDRA); website updates and contributions to EMCDDA 
publications such as Drugnet Europe.
During 2006 the RES unit improved the quality of a number of monitoring instruments 
based on cooperation between the EMCDDA and the future users of the instruments, 
the Reitox national focal points. In particular, the instruments used to monitor demand 
reduction activities benefited from a shift in focus for the unit towards identifying and 
publicising ’best practices’. The Exchange on Drug Demand Reduction Action (EDDRA) 
continued its evolution from an inventory of evaluated studies towards an integrated 
system of information that supports science-based practices in demand reduction. A 
section of the EMCDDA’s website, the Prevention and Evaluation Resources Kit (PERK) 
(16), is a core element in this approach. PERK was further developed during 2006 
following intensified contacts and discussions on research issues with the European 
Commission’s DG Sanco and other organisations.
Another key activity in the RES unit during 2006 was the revision of the reporting tools 
on prevention, comprised of one standard table and three structured questionnaires. 
Following collaboration among EMCDDA staff, experts and national focal points, the 
two structured questionnaires were merged and the scope of standard table 19 (school 
programmes) was redefined to achieve greater clarity. The unit also performed work 
on the EU drug strategy and the EU action plan on drugs, contributing to the Centre’s 
drafting of nine thematic papers for the first European Commission Progress Review of 
the EU action plan on drugs. Specific activities were also targeted in a number of areas, 
such as the economic analysis of drug-related expenditure, and the problems of drugs 
and driving.
Improvement of data collection and development of new scope
The Annual report remained the main cyclical channel for reporting on the European 
situation as regards drug policies and laws, prevention, treatment, harm reduction and 
drug-related social reintegration. The RES unit drafted the Selected issue: European drug 
policies — extended beyond illicit drugs? after organising a working group on the topic 
with interested members of the Scientific Committee in February 2006. The unit also 
contributed to the selected issues on gender perspectives on drug use and drug use within 
recreational settings. 
A general revision and improvement of the tools to monitor prevention was launched in 
2006. This process involved EMCDDA staff, national focal points and prevention experts. 
It led to the development of a comprehensive strategy for information collection, and to 
the approval by Member States of revised questionnaires on selective prevention and 
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universal prevention, including data collection on standardised prevention programmes 
in schools. The Exchange on Demand Reduction Action (EDDRA) (17) was placed under 
review in 2005, and work continued on EDDRA in 2006. The review proposed a plan for 
a new online portal about science-based practices, including an outline of how existing 
EDDRA content could be revised and migrated into this portal. The concept was discussed 
at two different technical meetings: in September with representatives from nine countries 
and in October with EDDRA managers. A strategy for developing a portal, focusing on 
science-based practices, was adopted by all the parties involved. In addition, new quality 
criteria for EDDRA submissions, together with a new EDDRA reporting template, were 
adopted by EDDRA managers and national focal points.
Supporting the new online portal about science-based practices, the Prevention and 
Evaluation Resources Kit (PERK) was further expanded to include the following: outlines 
for data presentation; updated reports on the state of selective and indicated prevention 
in the EU; documentation and training resources available to Member State professionals 
regarding the scientific basis of prevention. Environmental strategies (advertising bans, 
taxation, licensing etc.) were explored during the year in response to recent political 
developments, in particular a proposed EU-level strategy to reduce alcohol-related harm 
and a series of new, strict smoking bans in various Member States. The cross-substance 
impact of such strategies were discussed with experts and national focal points at an 
expert meeting, and a report on environmental prevention strategies of legal drugs 
(alcohol and tobacco) was prepared and is planned for publication during 2007.
Data collection was improved during 2006 in the areas of availability and provision 
of treatment, and also harm reduction responses. The RES unit cooperated with other 
EMCDDA units on the drug-related deaths, drug-related infectious diseases and treatment 
demand indicators. The unit’s contribution mostly involved analysing data submitted 
by the national focal points in three structured questionnaires: SQ 27 on treatment 
programmes, SQ 28 on social reintegration, and SQ 29 on reduction of drug-related 
deaths. Analysis was published in the 2006 Annual report, and related figures and 
data tables were prepared for the Statistical bulletin. In parallel, an assessment was 
made of new and potential information sources from other institutions that may be used 
to supplement the EMCCDA‘s own data; for example, statistical information on national 
consumption levels of controlled drugs from the INCB and vaccination coverage data 
from UNICEF. In response to a specific action in the 2006 work programme highlighting 
the need to monitor ‘cocaine use and responses to problematic cocaine use’, a literature 
review of cocaine and crack treatment responses was launched. The conclusions of this 
review will be made available in 2007, and are expected to improve the knowledge of 
the different types of treatment responses to problematic cocaine use in Europe.
The EU Action Plan on Drugs requests improved information on drug-related public 
expenditure. To address this need, 2006 saw the launch of a project to identify, develop 
and test a methodology at EU level for quantifying public expenditure in the field of 
drugs. The Centre appointed a new expert project manager in economic analysis early 
in the year, and the first fruits of the project were apparent by year-end. A methodology 
for data collection was drafted, placing emphasis on building a unified and standardised 
approach and on maximising the validity and cross-country comparability of results. Two 
further reports were produced in 2006: an expert document on cost of illness; and an 
initial analysis of the health economics of drug use services in Europe.
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Activities carried out by the RES unit’s legal team during the year included updates to the 
European Legal Database on Drugs (ELDD) to cover European legislation on three issues: 
personal possession and use of cannabis; hallucinogenic mushrooms; and drugs and 
driving. A conference on drug trafficking in the Balkan routes, organised by the Austrian 
presidency, prompted reflection on supply reduction activities. Contacts were made with 
European law enforcement agencies on the issue. The legal team was also called upon 
during 2006 to follow up the recast of the EMCDDA’s founding regulation. 
In addition to such routine tasks, the legal team investigated two specific issues during the 
year: the legal status of drugs testing (in the workplace, at schools, in prisons, roadside 
tests); and the legal framework of substitution treatment. The Centre participated at 
several meetings and conferences about these issues, including the Pompidou Group’s 
Ethics platform (18) and a Eurogip (19) debate. Furthermore, the legal correspondents’ 
meeting in 2006 was dedicated to the analysis of the legal framework of substitution 
treatment. The meeting also provided an opportunity to improve the structure of the legal 
correspondents’ network. Specific topic overviews on both drugs testing and substitution 
treatment were published in 2006 in the Centre’s European Legal Database on Drugs 
(ELDD). 
Cooperation
In keeping with its role as key provider of information on drugs in Europe, the EMCDDA 
continued its tradition of close cooperation with external bodies, particularly at the 
Community and United Nations levels. During 2006, the RES unit represented the Centre 
at the Council’s Horizontal Working Party on Drugs and other relevant EU meetings, and 
proactively supported the Austrian and Finnish EU presidencies with information and 
data. Contacts with the European Commission intensified during the year, in particular 
with DG Justice, Freedom and Security and with DG Sanco, and a formal working 
relationship with both Directorates General was established. This intense cooperation 
means that the Centre was invited to participate in several Commission working groups, 
including the EC inter-service group on drugs, the Steering committee for the evaluation of 
the EU action plan on drugs, the Selection committee of public health funded projects and 
the financial programme Prevention and Information.
DG Sanco collaboration:
• An advisory board position in the Network Project on Health and Social Exclusion 
‘Correlation’ (DG Sanco-funded).
• Discussion on the development of the online portal on science-based practices.
• Representation of the EMCDDA in the Coordination Group of the DG Sanco project to 
follow-up implementation of the Council Recommendation on prevention and reduction of 
health-related harm of 18 June 2003. Active technical input and support to this project 
was provided throughout the year and included the provision of datasets, facilitation of 
cooperation with the Reitox network, participation in coordination meetings and general 
feedback provided to the consultants working on the task.
UNODC collaboration:
• The United Nations Office on Drugs and Crime (UNODC) asked the EMCDDA to 
provide assistance in preparing the ten-year review of the implementation of the outcome 
of the twentieth special session of the United Nations General Assembly on the World 
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Drug Problem (UNGASS) held in June 1998. A first review of UNODC/EMCDDA 
comparable data was made during 2006 and a regional report will be delivered in 
2007 to the UNODC.
• Discussions were held with UNODC about ways to collaborate under the framework of 
the development of the online portal on science-based practices.
• The Centre provided input to the UNODC global treatment project Treatnet as one of 
the project’s international partners.
WHO collaboration:
• The existing good cooperation with the WHO Regional Office for Europe was 
maintained. Concrete collaborations included cooperation on the joint database on 
health in prisons, and participation in the Health in Prisons (HIP) conference and network 
meeting held in Romania during October 2006.
Other:
• The Centre continued to contribute various technical presentations at meetings of the 
Council’s Horizontal Working Party on Drugs.
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Reitox and international cooperation
Activities and results
The tasks of the Reitox and International Cooperation Unit, as its name suggests, cover 
two sectors of activities. Firstly, the unit manages the Reitox network of national focal 
points (NFPs) in the 25 Member States and Norway. This comprises daily interfacing 
with the Reitox network; training; financial and administrative management of grant 
agreements; quality assurance and capacity development. Secondly, the unit acts as the 
interface between the Centre and international organisations, both within the EU and 
beyond. This sector of the unit’s activities gives the Centre a diplomatic and ‘outreach’ 
role with the wider world. Tasks include: coordinating the practical actions linked to 
international cooperation, for example communication and administrative tasks linked 
to enlargement; contacts with international peer organisations and third countries; 
organising official visits to the Centre; technical cooperation with candidate countries 
(such as Turkey and Croatia) and potential candidate countries to the EU; and responding 
to information requests from third countries.
There were notable achievements for both sectors of the unit during 2006. With regard 
to Reitox these included: improving and simplifying the financial and administrative 
management of the Reitox grants, in particular the appointment of an assistant to manage 
this aspect of Reitox; improving quality assurance of the Reitox network, for which a 
dedicated quality assurance assistant was appointed during 2006; ensuring training and 
a smooth transition to new reporting tools on prevention; preparation for the planned 
switch to the new Fonte data processing tool. The International cooperation sector is 
becoming more important as the Centre matures and is increasingly seen as a key 
international actor and interlocutor in the drugs debate. In addition to continued contacts 
with the Centre’s long-standing international partners — such as the Pompidou Group, 
UNODC, Europol, Interpol, WHO and WCO — in 2006 a number of activities were 
carried out with CICAD (the Inter-American Drug Abuse Control Commission) and the 
Federal Drug Control Service of the Russian Federation. The Centre also played host to 
numerous diplomatic and expert delegations throughout the year.
Reitox 
Network management and grant agreements
Work in the area of network management concentrated in 2006 on improving the 
grant agreements system, both from the side of the EMCDDA as well as from the side 
of the NFPs. Internal and external processes were reviewed, and the problem of lack 
of human resources within the unit was addressed by the appointment of a financial 
and administrative assistant, who started working in October. Linked to this review, a 
special Reitox academy training seminar was organised in Larnaca in June 2006 for all 
countries. Additional templates and optional supporting tools were prepared for the 2006 
and 2007 grants, and all NFPs received bilateral quality feedback on their financial and 
administrative management of the grants in December 2006. This feedback included 
concrete suggestions and proposed solutions for preparing the financial documents to be 
presented with their request for the payment of their 2006 grants.
By the end of 2006, a solution was found for those countries that had experienced 
difficulties in the past in providing the EMCDDA with their requested administrative 
documents. The NFPs and the EMCDDA managed to simplify procedures where needed, 
and it was agreed that the EMCDDA would prepare in the first quarter of 2007 a manual 
for the administrative and financial management of the grant agreements by the NFPs.
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Quality assurance and capacity development
Recent restructuring in the unit, begun in 2005, has grouped together the unit’s quality 
assurance and capacity development activities. This is to ensure a strong link between the 
tasks, both of which are complementary and underpin the ongoing improvement of the 
Centre’s key indicators and core data. The recruitment of a quality assurance assistant 
was launched in 2005, and the new staff member joined the Reitox team in January 
2006. The unit is now better resourced to address the work involved in liaison with the 
26 Reitox NFPs, a number that will soon grow to reach 28 NFPs.
A quality assurance policy document was adopted by the Directorate of the EMCDDA in 
February. The document describes the various activities carried out within the framework 
of quality assurance, and provides a general guide for the Centre’s work in the area. 
It also clearly identifies the roles and duties of all internal actors involved in the quality 
reporting exercise. Following adoption of the document, several meetings were organised 
with project managers and data managers, resulting in a clear improvement and 
conceptualisation of the Quality report package presented to the NFPs in May 2006. 
The section of the EMCDDA public website on quality assurance was also revised and 
improved.
Contributing to the Centre’s improvements on the key epidemiological indicators, a new 
quality assurance product was prepared which provides a short overview of the status 
of the indicators in the Reitox network. The new product, Implementation need profiles, 
was conceptualised in March and April and sent to the Heads of NFPs in May. The 
need profiles were discussed at the Reitox meeting in November before being sent to the 
members of the Management Board. Implementation need profiles will be updated every 
year and included in the Quality report package.
As agreed during the heads of NFPs meeting in November 2005, the EMCDDA prepared 
in 2006 a methodology for revising its new reporting tools. The first revision exercise 
addressed the reporting tools on prevention (see previous RES unit section). The Reitox 
team contributed to this exercise. The new tools were adopted at the heads of NFPs 
meeting in May 2006 and the revision process was concluded at the Reitox meeting in 
November 2006, together with further revisions relating to EDDRA. Beyond prevention, 
the EMCDDA guidelines for national reporting were improved and adopted at the 
November meeting. Changes addressed in particular Chapter 4 on Problem drug use 
and treatment demand population. 
The Centre’s Country situation summaries (20) were updated from September to 
November 2006. In order to avoid any confusion with the information presented during 
the November launch of the Annual report, their publication was delayed until January 
2007. These brief and concise overviews on the drug situation in the old and new EU 
Member States and Norway are published in English as well as the respective national 
languages of each country. They are compiled from national reports and standard tables, 
submitted through Reitox and produced in collaboration with the national focal points. 
The country situation summaries include all 25 Member States and Norway, together 
with the Bulgaria and Romania (which became Member States in January 2007) and are 
accessed via an enlarged EU and individual country maps. As agreed with the European 
Commission, additional country situation summaries that were produced following the 
EMCDDA standards in the framework of the Community assistance programmes to the 
countries of the former Soviet Union have been included.
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The Reitox team provides training to NFPs via its Reitox academies. The Reitox team 
continued to promote ‘cluster’ training initiatives and national academies, and this 
decentralised approach was also adopted for training activities organised in the 
framework of the technical assistance projects with Bulgaria and Romania, as well 
as with Croatia and Turkey. In order to improve the quality and relevance of training 
activities within the framework of the Reitox academy and the Phare project, a project 
manager from a scientific department was closely associated with each academy to assist 
with the contents, methodology and selection of trainers. 
Following analysis of the training needs of all 26 NFPs, a Reitox academy on Grant 
agreements management was organised in Larnaca in June 2006. In addition to this 
plenary academy, several EU training initiatives were organised for national experts. 
These included: direct support to the Slovak NFP to strengthen the knowledge and 
skills in drug epidemiology for a new staff member, based on sending the new Slovak 
epidemiologist to the French NFP for three days’ intensive training; and a national Reitox 
academy in Lisbon in May on Community assessment and planning of services, which 
comprised a joint EMCDDA-IDT training programme on rapidly assessing community 
needs for professionals in the field of drug demand reduction.
The unit also organised during 2006 a comprehensive evaluation of previous Reitox 
academies using a Europe-wide survey among former participants and national experts. 
This was done to assess previous training activities, and to cluster and better identify 
further national training needs. Preliminary results were presented at the Head of NFPs 
meeting in May and the final results were presented during the head of NFPs meeting 
in November. On the basis of these results, the unit launched a joint project together 
with the EPI unit to produce standardised methodological packages on the five key 
epidemiological indicators. These will include training materials and sets of scientific 
references. Calls for tenders were launched in the third quarter of 2006, and the 
products will be available in the third quarter of 2007.
International cooperation
The EMCDDA maintained an active presence on the circuit of international drugs 
meetings during 2006. These included: the Pompidou Group’s Ministerial Conference and 
Permanent Correspondent meetings as well as various expert meetings; the Commission 
on Narcotic Drugs; the World Customs Organisation’s Enforcement Committee, Interpol’s 
General Assembly, and CICAD’s Regular Sessions. An EMCDDA delegation visited 
Europol headquarters in The Hague, while Europol staff members attended several 
meetings in Lisbon. The EMCDDA also attended the High-Level meeting of the EU-Latin 
America and Caribbean Cooperation and Coordination Mechanism on Drugs in Vienna. 
Cooperation framework agreements were negotiated with relevant international partners, 
such as the World Customs Organization, the European Centre for Disease Prevention 
and Control (ECDC), and the Federal Drug Control Service of the Russian Federation.
Relations with CICAD (the Inter-American Drug Abuse Control Commission) merit 
particular attention, and bode well for stronger cooperation with Latin American 
countries. During 2006 cooperation with CICAD included: a staff training visit by CICAD 
delegates to Lisbon; CICAD participation at the EMCDDA expert meetings on treatment 
demand and on drug-related mortality indicators; the Centre’s hosting of a meeting 
between the UNODC and CICAD, followed by a trilateral meeting on drafting a joint 
handbook on establishing and assessing national monitoring centres.  
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The EMCDDA received an increasing number of official and study visits in 2006. 
Delegations were welcomed, for example, from Germany’s National Drug Coordinator 
and Bundeskriminalamt, from the NFPs of Turkey and the United Kingdom, as well as 
from political representatives of third countries such as Cuba’s vice-minister of Health, 
Argentina’s Secretary of State in charge of the fight against drugs, and a delegation from 
the United States Congress. The Ambassadors to Portugal of the United Kingdom, Ukraine 
and Colombia, as well as a member of the Korean Embassy in Madrid, visited the 
Centre. On the International Day against Drugs (26 June), a reception for the diplomatic 
corps in Lisbon took place at the EMCDDA’s headquarters. Several academic and expert 
delegations also visited the EMCDDA during 2006. These included the Bergen Clinic 
Foundation and representatives of the universities of Rotterdam, Ghent and Brasilia, 
together with Australian and Japanese drug experts. 
With regard to enlargement activities, negotiations between the Commission and 
candidate or third countries for participation in the EMCDDA were followed up at various 
times during the year. In particular, the role and activities of the EMCDDA were presented 
to candidate countries and to third countries which have officially applied for membership 
of the EMCDDA. Formal relations were initiated in some cases. Activities included 
tracking the evolution of pre-accession instruments, including the programmes supporting 
the Western Balkans, and the preparation of a technical assistance programme based on 
the Phare model. The unit also carried out Community-level actions towards third countries 
in fields where an EMCDDA contribution was expected or in fields that form an integral 
part of EU drug policy. Thus the Centre continued to exchange information with those 
Community programmes that are responsible for implementing the EU policy on drugs in 
third countries.
Technical cooperation
The Reitox unit completed the technical assistance project to prepare Bulgaria and 
Romania for their participation in the EMCDDA (Phare III). The project began in May 
2005 for a duration of 18 months with a budget of 300,000 euros, and was completed 
by the end of December 2006. The recommendations made by the EMCDDA were 
included to a large extent in the Monitoring report on the state of preparedness for EU 
membership of Bulgaria and Romania presented by the Commission in May 2006. At the 
end of 2006, an external evaluation exercise was launched in order to assess the state of 
preparedness of the NFPs in Bulgaria and Romania.
In June 2006 a new project was started with Croatia and Turkey to establish and 
strengthen the national focal points and national drug information networks and to 
integrate them further into the Reitox network. The project follows the decision of the 
European Commission of 9 December 2005 to establish a multi-beneficiary programme 
on the participation of Croatia and Turkey in certain Community agencies, including the 
EMCDDA (Phare IV). This project will last until the end of December 2007 and has a 
budget of 500,000 euros. Two country coordinators were appointed and missions were 
organised to Croatia and Turkey in order to produce a re-assessment report for each 
country and a joint work programme for 2006–2007. The joint programme is expected 
to be formally approved by the authorities of the two countries at the beginning of 2007. 
In the context of the Communication of the Commission on the Participation of the 
Western Balkans in some EU agencies, and at the request of the European Commission, 
the Reitox unit was invited to participate in a meeting in the former Yugoslav Republic 
of Macedonia, in the framework of a training activity organised by TAIEX. This meeting 
provided the opportunity to present the work of the EMCDDA and the future CARDS-
EMCDDA project to all the countries of the region.
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Scientific partners and documentation 
Activities and results 
The Scientific partners and documentation (SCD) unit was created in 2005. Its mission is 
to encourage scientific excellence, to facilitate knowledge transfer between researchers 
and policymakers, and to increase transparency in the Centre’s scientific work. The 
unit provides direct support to the EMCDDA Scientific Committee and also includes the 
Centre’s documentation centre. A concept paper for the unit was approved by the Heads 
of unit at the beginning of 2006, and established three main areas of work: a web-based 
interactive research information system; relations with the scientific community; library 
and documentation services. The unit’s clients can broadly be described as ‘researchers’, 
embracing the Centre’s own scientific staff, policymakers, and staff at the Reitox national 
focal points.
2006 was very much a start-up year for the unit. In January, the unit consisted only of the 
head of unit and a library assistant. A post for a research information manager was filled 
in April yet became vacant again in October. A post for the head of the documentation 
centre was filled in September and the post for a secretary in November. Early work for 
the unit during 2006 included investigating the needs for information and exchange on 
drug-related research, internally as well as externally and to evaluating the Centre’s past 
and current activities in the area of drug-related research. An internal advisory group 
was set up to encourage knowledge transfer between the Centre’s EPI and RES units. 
Cooperation was also sought with the European Commission, particularly DG RTD and 
other international organisations, such as the Pompidou Group, WHO and UNODC, and 
European research institutions and networks. Contact was also established with other EU 
agencies with a scientific and information mandate.
In order to set up a concept for a web-based research information system, the SCD 
unit reviewed existing services and interviewed staff and external scientists about their 
research information needs. At present no overview of European drug-related research 
exists. The investigations revealed that it would not be easy to create an overview 
since the information as well as the information sources are both scattered and of 
varying quality. Researchers indicated two main needs: to contact other researchers 
doing similar work; and to obtain information about funding sources. On the basis of 
the investigations made, a pilot section was set up on the Centre’s intranet containing 
news items, information about EU research programmes, research organisations and 
networks, forthcoming research events as well as indexing and abstracting databases 
and publications. 
The 7th framework programme for research was launched at the end of 2006. 
Throughout the year, contacts were made with DG RTD of the European Commission, 
particularly the Social Sciences and Humanities (SSH) research area, in order to examine 
the possibilities for drug-related research within the 7th framework programme. In 
connection with the Scientific Committee meeting in December, a representative of DG 
RTD visited the Centre and delivered a presentation to scientific staff.
The SCD unit is involved in two ‘platforms’ of the Council’s Pompidou Group: the 
Research platform (21) and the Ethics platform (22). Useful discussions were held with 
the Research platform about the respective role of the two organisations. The EMCDDA 
was involved in the preparations of the Pompidou Group Online register of current drug 
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research (23) which was launched at the end of the year. The Ethics platform finalised 
its deliberations on drug testing in schools and proceeded to explore the question 
of drug testing at the workplace. The EMCDDA contributed with expert papers and 
documentation (see RES unit section).
Scientific journals are a vital element of scientific work. The 2006 annual meeting of the 
International Society of Addiction Journal Editors (ISAJE) (24) provided the opportunity to 
introduce the EMCDDA and its work to the editors of drug and alcohol journals. It was 
agreed to sustain the exchange between the EMCDDA and ISAJE and an editor of the 
journal Addiction agreed to give talks on scientific publishing to EMCDDA staff. 
Several drug-researchers’ networks exist in Europe. During 2006 the unit intensified 
contacts with a number of these. The Network of European Researchers in the Use of 
Drugs and Alcohol (NERUDA) brings together researchers working on funded research in 
drugs and alcohol to examine issues in substance use and misuse from a cross-European 
perspective. NERUDA collaborates on different topics of interest to the EMCDDA, e.g. 
youth, concepts of addiction and the social consequences of addiction. It also seeks to 
set up a European master’s programme on addiction. The EMCDDA follows this work 
with interest and agreed to host NERUDA meeting in Lisbon during 2007. The European 
Society for Social Drug Research (ESDD) held its annual meeting at the Instituto Superior 
de Ciências do Trabalho e da Empresa (ISCTE) in Lisbon.  EMCDDA scientific staff made 
presentations and attended the working sessions, while a reception was offered for the 
participants at the EMCDDA premises.
With the arrival of a head of the documentation centre in September, this EMCDDA 
resource began to revitalise its approach to library services. Communication between the 
documentation centre and staff has not been optimal in the past, yet it is now becoming 
more service- and client-focused. An inventory of needs was made in the third quarter, 
and gave guidance for future developments. It revealed the wide range of interests of 
staff within the overall field of ‘drugs and drug addiction’: medicine and pharmacology; 
law; psychology and behavioural disorders; pharmacology and toxicology; statistics; 
government policies and activities (national and supranational); the economics and 
implementation of drugs policies; crime and enforcement. Services were implemented 
to serve staff with thematic literature searches, using databases containing quality, peer-
reviewed items. In particular, staff requested up-to-date information and alerts to new 
developments in their field. Training and assistance in the use of databases have been 
offered and readily accepted by staff. However, a serious obstacle is the fact that the 
documentation centre is in a separate building from its main clients, the scientists and 
researchers. Reuniting the Centre in a single premises is keenly awaited. 
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Communication 
Activities and results 
The Communication unit (COM) aims to produce both printed and online publications 
addressing the most important aspects of the drugs phenomenon in Europe. It also plays 
a wider role in marketing and communications for the Centre, with varied tasks including 
editorial services, media relations, marketing, internal communications, institutional 
relations, public relations, knowledge management and events. 
The unit is able to report a number of notable achievements in 2006. Perhaps the most 
visible achievement was to improve the positioning and to increase the media coverage 
of the Annual report. In November 2006 the Centre achieved a level of interest for the 
Annual report that strongly exceeded expectations, both in terms of breadth and depth 
of coverage. The Centre’s statistical data is now increasingly being referenced by media 
outlets in the context of day-to-day drugs news. The Fonte project also saw substantial 
progress during the year. It evolved from the specifications phase into a user-friendly, 
clickable software product to be tested by its core users, the Reitox network. 
Other important developments during the year included enhancements to the EMCDDA’s 
public website, including completion of a project begun to improve the ‘linkage’ of 
the Annual report with the data in the online Statistical bulletin. The website was also 
enhanced by a focus on short, summative information, notably updated Country situation 
summaries and new Drugs profiles. The EMCDDA’s intranet was also substantially 
improved, reflecting the expediency in 2006 of providing a wave of new recruits with 
operational information, and to encourage stronger flow of information across units. 
Other key tasks in 2006 included much editorial work on the Centre’s planned cannabis 
monograph.
Publications
The EMCDDA public website registered just over 2.5 million visitors during the course 
of 2006, which corresponds to approximately 7,000 unique visits per day. It remains 
the key channel for publishing information and publications about the centre and the 
European drugs situation. The website is subject to several updates each day, ensuring 
an up-to-date overview of the Centre’s activities, events, administrative processes, 
projects and scientific outputs. Besides the Annual report package, major web products 
in 2006 included the updating of Country situation summaries (25 Member States and 
Norway, online in January 2007), preparation of Drugs profiles, that is short summaries 
of scientific information on six substances: amphetamine, cannabis, cocaine/crack, 
heroin, MDMA and methamphetamine (published in March 2007); significant updates to 
the European Legal Database on Drugs (ELDD) and Prevention Evaluation Resources Kit 
(PERK); together with a new RSS (really simple syndication) newsfeed for the website. The 
website was also among the first EU agency websites to be migrated to the new domain 
name europa.eu in May 2006. 
As in 2005, the 2006 Annual report was coordinated, edited and published in 23 
languages (all EU languages except Maltese plus Norwegian and Turkish). The Annual 
reporting package in 2006 comprised: the Annual report in 23 languages (printed 
publication and website); three Selected issues (printed publication and website); the 
Statistical bulletin (website); Country data profiles; Reitox national reports; a Powerpoint 
presentation summarising the key findings (23 languages); a press kit (23 languages) 
comprising four news releases (nos. 3,4,5,6), an address from the Centre’s director and 
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facts and figures sheet; a ‘podcast’ interview with the Centre’s director about the Annual 
report. Other publications included: the 2005 General report of activities, a thematic 
paper Hallucinogenic mushrooms: an emerging trend case study; four editions (53, 54, 
55, 56) of the Centre’s newsletter Drugnet Europe. Substantial editorial work was also 
carried out during 2006 on the Centre’s cannabis monograph. The product will be the 
longest ever produced by the Centre, and substantial comments and improvements to the 
chapters were made during 2006 by an external scientific editor. Publication is foreseen 
during 2007. As in previous years, editorial work by the unit also included linguistic 
editing and ‘clean-up’ of internal and administrative documents, for example the Staff 
policy plan 2008–2010 together with day-to-day communication and correspondence. 
Media relations
The Centre’s media relations activities in 2006 centred on the following: expanding 
the agency’s register of specialised media and improving press database management; 
producing press materials and enhancing their presentation online; improving the 
agency’s press monitoring capabilities. These goals fell under the three pillars of the 
EMCDDA Media relations strategy. 
Under the first pillar (‘Building sound contacts and relations with journalists’), the 
EMCDDA launched a project in February to track the most prominent multiple publishers 
(syndicates) and online news webmasters in the EU Member States on the principle 
that they could serve as important multipliers for EMCDDA news. A questionnaire to 
the national focal points (NFPs) yielded in April lists of these entities across Europe for 
inclusion in the press database ready for targeted press action in the Autumn. A strategy 
to overhaul the agency’s management of press contacts was drawn up in July aimed at 
achieving a more rapid and efficient delivery of press materials. This strategy, falling 
within a broader distribution and address management project, will be executed in 
2007.
Under the second pillar (‘Providing media-friendly information with clearly defined 
messages’), the agency produced high-quality press materials throughout the year 
totalling seven news releases and four fact sheets. In keeping with previous years, media 
actions in 2006 focused on two events: International day against drug abuse and illicit 
trafficking (26 June) — when the EMCDDA launched an emerging trend cases study 
on hallucinogenic mushrooms and hosted an event for Lisbon’s diplomatic corps; the 
November launch of the 2006 Annual report in November in Brussels. For the latter, four 
news releases were produced in 23 languages along with additional promotional items 
and materials. A press briefing and conference were held on 22 and 23 November 
following a presentation to the European Parliament. National events were organised, 
largely by the NFPs, in 13 EU Member States. Together these events led to unprecedented 
coverage of the report recorded in a 1,700-page press review. The structure and 
presentation of news material on the public website ‘press room’ were also overhauled 
taking up recommendations from a previous external analysis of the site, while the press 
section of the intranet was also improved.
Under the third pillar of the media relations strategy (‘Assessing impact via monitoring 
and press reviews’), the EMCDDA set up a free-of-charge monitoring service via the 
‘European Media Monitor’ project offered by the EU’s Joint Research Centre (http://
emm.jrc.it). This service, based on a keyword function in all EU languages, was up and 
running by March and considerably enhanced the agency’s ability to track articles citing 
the EMCDDA. This service was complemented by a second monitoring tool focusing 
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specifically on aggregating drug-related stories via RSS newsfeeds (using GoogleNews, 
Yahoo, etc.) and subscriptions to specialised newsfeeds from drugs blogs, libraries and 
journals. This tool, which tracks articles on the EMCDDA and drugs in general, has 
produced a corpus of European drug news that can be used not only to assess the impact 
of EMCDDA relations work but also to inform internal researchers and external journalists 
about ongoing drug publications. This responds to the objective listed in the media 
relations strategy ‘to anticipate journalists’ requests better through regular monitoring 
of drugs media coverage and political events related to the issue’. A total of six press 
reviews were compiled in 2006 (quarterly, 26 June, Annual report). 
In the second half of the year press actions were organised around two VIP visits to the 
EMCDDA: by the President Barroso of the European Commission and Commissioner 
Frattini of the DG Justice, Freedom and Security. A strategy paper on proactive media 
relations was also finalised. 
Marketing
In the first half of 2006, the Centre’s marketing activity focused on updating the 
corporate identity materials (logos, promotional packs, etc) and the launch of tenders 
following the change of the EMCDDA domain name in May to emcdda.europa.eu. The 
range of EMCDDA-branded promotional literature was further developed in 2006. 
This included the release of a brochure ‘Monitoring new drugs’ in February describing 
the workings of the May 2005 ‘Council Decision on the information exchange, risk 
assessment and control of new psychoactive substances’ and the publication in November 
of ‘About the EMCDDA’ a brief presentation of the agency in Bulgarian, Romanian and 
Turkish. 
The EMCDDA displayed its publications at the Frankfurt Book Fair in October and 
produced a new exhibition stand and Annual report promotional ‘towers’ in November in 
preparation for a three-day exhibition of EMCDDA products at the European Parliament 
during the Annual report launch. In December, EMCDDA staff also participated in the 
exhibition Online Information 2006 in London on a joint stand with other EU agencies, 
where it promoted its online products, primarily the multilingual Annual report information 
package.
Promotional mailings publicising the Annual report were dispatched in November to 
scientific journals and youth media. New products were also promoted throughout the 
year via the newsletter Drugnet Europe and the public website. In the context of the 
project Representing the EMCDDA, a Powerpoint presentation on the 2006 Annual 
report findings was compiled in 23 languages, primarily to ensure a common corporate 
presentation of the product at the European and national launches.
In the context of the joint EU agencies’ information activities, the EMCDDA participated in 
two meetings in January and July and in a number of ensuing communication initiatives. 
The most prominent of these was the month-long advertising campaign launched on 1 
December aimed at informing European citizens about the activities and services of the 
decentralised EU agencies. Throughout that month, a print advertisement with the slogan 
‘Whatever you do — we work for you’ appeared in the in-flight magazines of some of 
the larger European airlines, at a time when millions of Europeans were travelling for the 
festive season (http://europa.eu/agencies). The EMCDDA also provided regular input 
as member of a steering group to two forums where the agencies were given privileged 
access in 2006: the European Commission’s (DG-COMM) External Communications 
Network (ECN) and its regular meetings with Euronews. At the October meeting of the 
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Heads of EU agencies, the EMCDDA was nominated one of seven members of a working 
group to provide input to Commissioner Wallström on how to best incorporate the 
agencies into the wider EU communication strategy. 
Distribution
EMCDDA distribution activities in 2006 concentrated on improving the general 
management of contacts. An analysis of the various mailing lists stored at the EU 
Publications Office led to major restructuring. This was followed by additional updates 
and setting up new lists with the aim of better targeting publications. At the same time 
an address management project was launched in cooperation with the ICT unit to more 
efficiently handle addresses within the agency for different approaches such as mass 
e-mailing, faxing and mail merging. A call for tender was prepared for launch early in 
2007.
The 2006 Annual report was published in 23 languages with a total print run of 31,810 
copies (8% more than in 2005). First distribution orders were already placed before 
the actual launch date in order to support events (e.g. the 12 national launches and the 
presentation to the European Parliament), to provide focal points with sufficient stock and 
to provide the EMCDDA statutory bodies with advance copies. The general distribution 
to mailing list subscribers followed in the week of the launch itself. Numbers provided by 
the Publications Office three weeks after the launch show that a little over 25,000 copies 
of the Annual report had been distributed, corresponding to 80% of the total print run.
Interinstitutional communication
The EMCDDA collaborated with the Committee on Civil Liberties, Justice and Home 
Affairs of the European Parliament in the context of the presentation of the Annual report 
on 22 November, the eve of the official press launch. In line with an EMCDDA strategy 
to increase the impact and visibility of the EMCDDA Annual report by boosting the 
national component, national parliamentarians were invited to the presentation. National 
representatives were able to intervene on the content of the report alongside members 
of the above Committee. The presentation was preceded by a lunch for national and 
European parliamentarians where the EMCDDA described its work.
Eleven EU Member States (Czech Republic, Denmark, Estonia, Greece, Ireland, 
Cyprus, Latvia, Lithuania, Luxembourg, the Netherlands, and Portugal) as well as the 
EU candidate countries Bulgaria and Romania organised national presentations of the 
Annual report. The majority of events were organised by, or in collaboration with, the 
national focal points. Some of them placed their own national drug situation in the 
European perspective by simultaneously launching national reports. The events enjoyed a 
high profile with the participation of Ministers and other senior officials in the drugs field. 
The EMCDDA provided human and logistical support for these events according to the 
requirements of the national authorities.
Fonte
Fonte is the centrepiece of the Centre’s currents improvements in data collection, 
processing and distribution, requiring substantial input from all units in the Centre. 
It comprises a web application with a linked database for collecting and storing the 
EMCDDA’s key data. It will be used for the three main cycles of data handling: collecting 
data, validating data and making data accessible to stakeholders. Once fully launched, 
Fonte will rationalise and streamline the EMCDDA’s workflows, and will facilitate its 
scientific work both internally and with partners. 
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2006 saw the programming of the Fonte web application and the migration into the 
Fonte database of historical data collected prior to 2006. Meetings with the contractor, 
the Portuguese IT company Pararede (25), began in January. An internal Fonte steering 
group was set up to co-ordinate work on the application from all the Centre’s units 
and to assess the delivered application as provided by the contractor. During 2005, 
the functional specifications of Fonte had been prepared. These were finalised early in 
2006, enabling Pararede to begin programming. The application was delivered in four 
incremental software modules with the first delivery in the beginning of August.
Tests were performed exclusively by the steering group from August onwards. Following 
the delivery of the full version at the end of the year, tests were expanded internally to 
include project managers and assistants. In October and November EMCDDA assistants 
and project managers created the electronic versions of the Centre’s Standard Tables 
and Structured Questionnaires, now referred to as ‘templates’ in Fonte. These templates 
were necessary in order to map the migration of data collected through other means into 
the Fonte database which was carried out by the contractor in close co-operation with 
EMCDDA staff members. 
By the end of 2006 the EMCDDA received a functional version of Fonte containing 
data that had been collected prior to 2006. Thus the EMCDDA had in its possession a 
modular web application and database reflecting the Centre’s workflows. 
A brief overview of the workflow is as follows: (i) templates are created by assistants 
or project managers (ii) templates are approved by the Reitox project manager (iii) 
the Reitox project manager activates the template in Fonte, enabling the national focal 
point (NFP) to complete it and submit a report (iv) the report is submitted by the NFP 
(v) a process of validation and revalidation begins: relevant EMCDDA and NFP staff 
members have access to the report (vi) once the data is fully validated, the responsible 
project manager flags the report as ‘concluded’ (vii) the report can now be accessed and 
retrieved by other stakeholders (e.g. other NFPs or EMCDDA staff members). The result of 
this workflow is that key data in the field of drugs and drug addiction is centralised in a 
single place, and that the process is tracked at each stage. Fonte thus constitutes a major 
leap forward in the EMCDDA’s aim to provide a unique and comprehensive data and 
knowledge base. 
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Supporting activities 
Administrative support
Activities and results 
The Administration unit was restructured in 2005. During 2006 focus was placed on 
improving the execution of the EMCDDA budget and work programme. Furthermore, 
attention was given to the improvement of EMCDDA procedures and instruments 
for internal control and management, particularly in the area of human resources 
management. These tasks implemented the action plan adopted by the EMCDDA 
management board early 2006 in order to follow up the recommendations resulting from 
an audit carried out by the Internal Audit Service of the European Commission (IAS) on 
the EMCDDA internal control system.
Planning, evaluation and legal matters
In 2006 work in the area of planning, evaluation and legal matters focused on the further 
improvement of the procedures for budget planning and management. Special attention 
was placed upon the following: measures aimed at anticipating and rationalising the 
planning and execution of the tendering process for the implementation of the work 
programme; reporting on budget execution; the adoption of possible corrective measures 
for budget management, i.e. transfers and re-assignment of appropriations. With regard 
to legal matters, 2006 activities included in particular: an assessment of the legal 
aspects of the implementation of the staff regulations; the recast of the Centre’s founding 
regulation; and the contractual operations relating to the new EMCDDA premises, the 
Ribeira das Naus complex. At the end of 2006 the EMCDDA contributed to the European 
Commission (DG Justice, Freedom and Security) for the tendering process aimed at 
selecting a contractor to carry out an external evaluation of the Centre’s activities.
Human resources management
Work on the implementation of the reform of the EU Staff Regulations, which entered 
into force in May 2004, continued throughout the year and is expected to be finalised 
during 2007. The capacity of the human resources management sector was strengthened 
by the recruitment of a new head of sector. An evaluation of internal human resources 
processes — to include recruitment, appraisal of staff and promotions — was carried out 
to further improve existing rules and processes. Best practices were developed in order to 
maximise the use of the existing resources, i.e. the creation of comprehensive databases 
for staff management. Attention was given to improvement of communication with staff 
as well as circulation of information. A welcome package for newcomers was developed 
and a section of the EMCDDA intranet was created for personnel matters. In this context, 
special attention was devoted to further developing team spirit and a pleasant working 
environment. 11 selection procedures were successfully carried out and 18 new staff 
members were appointed at the EMCDDA during the year 2006.
Financial management and accounting 
The internal capacity of the financial management sector was further strengthened and 
reorganised to better cope with the workload entailed by the management of payments 
and procurement operations. As regards payments-related tasks, the sector is now better 
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able to manage information on beneficiaries and legal entities, and to support the refund 
of mission- and meetings-related expenditure. The new rules and procedures for accrual 
accountancy were implemented. To prepare for the new accounting system and the 
implementation of ABAC, a mailing was sent out to all third parties in order to request 
the legal entity file form and update banking details. Specific measures were taken to 
improve the execution of the EMCDDA work programme and budget, together with the 
processes for financial and contractual management and internal control.
Infrastructure and logistics
The infrastructure and logistics unit placed specific focus during 2006 on the improvement 
of health, safety and security at work. Fire wardens were trained, and pincode doors 
for one of the buildings were ordered. To provide a more efficient service to staff, a 
meeting-room reservation system was developed, together with an intranet page for 
matters relating to managing infrastructure and logistics. New rules for inventory and 
asset management were implemented and a physical inventory check was conducted 
successfully. One of the two vehicles that comprise the EMCDDA fleet was replaced. 
The EMCDDA joined the inter-agency Greening Network set up and organised by the 
European Environment Agency for and held its first internal greening workshop. The aim 
of the Greening Network is to reduce pollution and building-related utility costs. 
The project for the new EMCDDA headquarters has progressed. After the initial political 
meetings, technical and security steering meetings were held in mid 2006. Construction 
works started in September 2006 and the complete architectural design was approved 
in November by Lisbon City Hall. The completion of the project is foreseen for the end 
of 2007, under the Portuguese Presidency of the European Union. To prepare the future 
move to the new premises, several activities were launched at a technical level in close 
co-operation with EMSA, the other EU agency with which the premises will be partially 
shared.
Information and communication technology 
The bulk of the ICT sector’s work in 2006 provided routine support to the Centre’s 
operations: network and server administration; web-related projects and services, in 
particular the future central data collection application, Fonte; office hardware and 
software; the ICT helpdesk. Expansion of the Centre’s second office also continued during 
2006, requiring significant use of standard ICT resources.
A key objective of the ICT sector during 2006 was to continue the adoption of best 
practices, with a focus on the use of the Information Technology Infrastructure Library (ITIL) 
(26), a standard ICT management framework. A seminar was organised on ITIL early 
in the year, and a number of best practice initiatives were undertaken. These included: 
introducing a permanent presence of helpdesk staff in the second building; acquisition 
of new incident management software to be deployed in early 2007; creation of a 
new Project Management Office to apply project management standards to ICT-related 
activities; work on business continuity, including replacing out-of-date server hardware, 
adding internet equipment (especially for Fonte) and electrical works at the data centre. 
Significant work took place in the area of information security: the role of Security officer 
was strengthened; data security and the security of electronic systems in general was 
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enhanced, including the adaptation of a custom notification tool for the EMCDDA data 
protection officer; and an e-security strategy was developed with an external partner. 
A number of specific activities merit attention. The website, intranet, Reitox extranet 
and related services, and the Fonte project in particular continued to required 
significant support in 2006. In May the EMCDDA changed its primary domain for 
email and websites from emcdda.eu.int to emcdda.europa.eu and was among the first 
EU institutions to perform the migration, thus participating in the effort to provide the 
European institutions with a single domain under europa.eu. The reporting platform 
used for financial reports in conjunction with the Centre’s budgetary software was 
upgraded in 2006. The aim is to widen the range of its potential usage to other areas 
of the EMCDDA’s work. This will gradually be introduced in 2007. The ICT sector also 
presented a systematic overview of all work processes at the EMCDDA, in order to map 
all projects, stakeholders, processes and existing services at the Centre. This overview 
will prove essential to developing ICT service quality, and is also beneficial both for 
automation of work processes at the Centre and for drafting a proposed business 
continuity plan.
Chapter IV: Statutory bodies and executive management 
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Chapter 4 
Statutory bodies and executive management 
Management Board
Main decisions 
At its 32nd meeting in Lisbon on 11–12 January 2006, the Management Board adopted 
a budget of 12,621,125 euros for 2006 (25 Member States and Norway), on the 
basis of an EC subsidy of 12,100,000 euros. The work programme for 2006, which 
was approved by the Scientific Committee, was discussed in parallel with the budget. 
The work programme took into account the results of replies by 16 Board members to a 
questionnaire-based ranking exercise on the EMCDDA’s activities of the previous year. 
The work programme was adopted by written procedure on the basis of the formal 
opinion of the European Commission after the meeting. 
The Management Board also adopted a preliminary draft budget for 2007 on the basis 
of an EC subsidy of 13,200,000 euros. This is the first budget of a new three-year work 
programme and aims to strengthen the scientific capacity of the Centre. The Management 
Board decided to maintain in 2007 the same total amount of appropriations earmarked 
under the 2006 budget for the EMCDDA financing of the Reitox national focal points, 
independent of the increased number of Member States. The adhesion of Bulgaria 
and Romania to the European Union will thus entail a slight reduction of the EMCDDA 
financing to each national focal point in 2007.  The Management Board renewed the 
mandate of Mr Lawrence (UK) as member of the Bureau for 2006 for a third year. 
Mr Christian Muller, Audit Supervisor of the Internal Audit Service (IAS) of the European 
Commission, presented the first internal audit report conducted from January to February 
2005 at the EMCDDA, together with its recommendations. In response, the EMCDDA 
developed an action plan over three years to reply to the recommendations made by 
order of priority. Measures would be implemented in three phases: until mid 2006, until 
the end of 2006 and until the end of 2007.  The Director regularly would also present 
a progress report on these measures to the Management Board. Further to one of the 
recommendations made, the Board discussed and adopted a document outlining the 
competences of the Management Board, the Bureau, the Budget Committee and the 
Director in the context of the EMCDDA regulation in force.   
The Management Board welcomed the new organisational structure of the EMCDDA. The 
main innovation lay in merging the four previous scientific departments into two units 
(‘Epidemiology, crime and markets’ and ‘Interventions, law and policies’), together with a 
support unit (‘Scientific Coordination and Documentation’). The Heads of these two main 
units are also responsible for transversal scientific cooperation at the Centre.
The EMCDDA rules for the implementation of Regulation (EC) No 1049/2001 of the 
European Parliament and the European Commission with regard to public access to 
documents were commented upon and adopted by written procedure after the meeting. 
This decision required that the final agendas and final minutes of Management Board 
meetings be published on the EMCDDA website from July 2006.
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In the 33rd Management Board meeting from 5–7 July, the Management Board adopted 
the three-year work programme for 2007–2009. In summary, the new work programme 
concentrates on core business, investing more effort in analysis and in ensuring that 
information is effectively disseminated. The work programme includes an analysis of 
implications of the recast of the EMCDDA regulation, which entered into force at the 
beginning of 2007, and of potential risk factors likely to influence its implementation.
The Management Board renewed the mandates of Mr Franz Pietsch (AT) and Mr Kyriakos 
Veresies (CY) as members of the Bureau exceptionally for one year and a half, to allow 
elections to always take place during the December Management Board meeting. 
Detailed practical arrangements for future elections of the Chair and Vice-Chair were 
also set up. The role and functioning of the Management Board within the current legal 
framework was also discussed.
In the field of international cooperation, the Management Board agreed with a draft 
Memorandum of Understanding between the EMCDDA and the World Customs 
Organisation. It was also decided that the early cooperation with the Federal Drug 
Control Service of the Russian Federation should be formalised, in close cooperation with 
the Management Board and the services of the European Commission. 
The Management Board gave a favourable opinion on the 2005 final accounts, and 
adopted the 2005 General report of activities. The report included for the first time 
the annual report of the authorising officer. The Board amended the 2006 budget to 
including the financing to an amount of 500,000 euros by the European Commission of 
a technical assistance project with Croatia and Turkey under the Phare programme. 
During its 34th meeting, the Management Board re-elected on 13 December 2006 the 
Chair, Mr Marcel Reimen (LU), and the Vice-Chair, Mr Ralf Löfstedt (SE), for a second 
three-year mandate (2007–2010). Mr Piotr Jablonski (PO) was elected member of 
the Bureau for 2007. Mr Claude Gillard (BE) was confirmed for a second three-year 
mandate as member of the Budget Committee, and re-elected among its members as 
Chair.
A budget of 13,511,706 euros for 2007 (27 Member States and Norway) was adopted 
on the basis of an EC subsidy of 13,000,000 euros. The 2007 work programme was 
welcomed for its output-oriented approach and its coherence with the 2007 budget, 
of which it includes in annexe an activity-based presentation. The Board adopted 
a preliminary draft budget of 14,077,579 euros for 2008 (27 Member States and 
Norway) with an EC subsidy of EUR 13,400,000 euros.
The Board also approved a staff policy plan of the agency for the years 2008–2010. All 
agencies needed to present their work programme for 2007 and a three-year staff policy 
plan to the European Parliament in order to have the technical reserves on their 2007 
budgets lifted. 
The Director was mandated to sign a Memorandum of Understanding with the Federal 
Drug Control Service of the Russian Federation, as well as a cooperation agreement with 
the European Centre for Disease Prevention and Control (ECDC), another EU regulatory 
agency. In view of the recast of the EMCDDA regulation, which stipulates a Scientific 
Committee composed of at most fifteen well-known scientists, a working group was set 
up to establish guidelines for the selection of these scientific experts. Board members 
Mr Richard Muscat from Malta and Ms Katalin Felvinczi from Hungary are part of this 
working group. 
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Bureau 
Main decisions
In 2006, the Bureau met five times in Lisbon (27). The Bureau usually meets in the 
morning before each Management Board meeting, to discuss the agenda items of the 
Management Board meeting and to provide advice to the Director. It also meets in two 
separate meetings to comment draft documents for Management Board meetings. 
The European Commission informed the Bureau at its meeting on 18 May about the 
second external evaluation of the EMCDDA to take place in 2007. The EMCDDA 
participated to the value of 30,000 euros of the 2006 budget in this joint exercise 
between the Centre and the European Commission. The Bureau determined practical 
arrangements concerning simultaneous interpretation at the Management Board, Bureau 
and Budget Committee meetings. It was further agreed that the Chairman should, on the 
basis of a proposal by the Director, decide on a case-by-case basis on which agenda 
items of Management Board meetings a Staff Committee representative could attend as 
observer. 
The Bureau adopted on 26 October a budget transfer for an amount of EUR 100,000 
euros from Title 1 to Title 2 of the 2006 budget. The salary-related expenditure for 
contractual agents initially foreseen could not be fully executed until the end of the year, 
and at the same time it was necessary to cope with supplementary needs for supplies and 
services to ensure the proper functioning of the EMCDDA. 
(27) 11 January, 18 May, 5 July, 26 October, 13 December.
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Director
In accordance with the Centre’s founding regulation, the Director is responsible for: a) 
preparing and submitting the Management Board proposals for deliberation as well as 
for implementing the Board’s decisions; b) deciding on staff matters; c) managing the 
Centre’s day-to-day activities; and d) representing the Centre externally. 
Preparation and implementation of Board’s decisions
In 2006, the Director implemented the 2006 work programme and budget; prepared 
and submitted to the Board for approval the 2007–2009 and 2007 work programmes, 
the 2007 budget and the 2008 preliminary draft budget. Furthermore, the Director also 
submitted to the Board for approval: the 2005 General Report of Activities; an action 
plan to implement the recommendations of the Internal Audit Service; a 2008–2010 Staff 
policy plan; a Cooperation agreement with the European Centre for Disease Prevention 
and Control (ECDC), a Memorandum of Understanding with the World Customs 
Organization (WCO) and a Memorandum of Understanding with the Federal Service for 
Narcotics Traffic Control (FDCS) of the Russian Federation. 
Staff matters and day-to-day administration 
In his capacity as both authorising officer and appointing authority (AHCC), the Director 
took 41 written decisions throughout the year, ranging from the adoption of a new 
detailed organisational chart to delegating some of his powers, with a view to achieve a 
more decentralised and more effective management of the Centre. Decisions included the 
adoption of internal administrative instructions and the publication of notices to ensure 
the functioning of the Agency.
Representation
The external activities of the Director were largely oriented towards building bridges 
and reinforcing cooperation, in particular with the EU institutions and Member States 
with a view to finding better ways to provide them with the service the require. 
They also covered meetings with representatives from third party organisations and 
countries oriented to building and improving partnerships in the area of drugs research, 
monitoring and policy. 
EU level representation
The key event as regards the European Parliament was the launch of the Annual Report, 
which was preceded by a pre-launch to the members of the Committee on Civil Liberties, 
Justice and Home Affairs. Following contacts established in this context, the Director had 
many bilateral meetings with MEPs throughout the year. The Director took part in two 
National Drugs Coordinators Meetings held under Austrian and Finnish presidencies 
of the Council of the European Union. With regard to the European Commission, the 
Director welcomed the President of the Commission, Mr Barroso, at the headquarters of 
the EMCDDA, and held two meetings with the Vice-president Mr Frattini, Commissioner 
for Freedom, Security and Justice (and in charge of the drugs portfolio), and also 
maintained regular contacts with Mr. Frattini’s cabinet, and met the Head of Cabinet of 
the Health Commissioner Markos Kyprianou. The Director maintained regular contacts 
with senior Commission officials within the Directorate for Civil Justice, Rights and 
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Citizenship at DG Justice, Freedom and Security as well as with DG Sanco, DG Budget, 
DG Research, DG Admin and DG Energy and Transport. At the level of the EU agencies, 
the Director participated at two meetings of the heads of agencies, and notably visited 
the European Centre for Disease and Prevention Control (ECDC) in Stockholm to examine 
possible synergies between both agencies. Mr Götz also had meetings in Lisbon with 
the Directors of the following EU agencies: the European Environment Agency (EEA), 
the Translation Centre (CDT), Eurojust and European Maritime Safety Agency (EMSA). 
Contacts with EMSA were frequent given the ongoing negotiations on the new Ribeira 
das Naus premises in Lisbon, which the agencies will share.
Member States 
A major share of the activities of the Director at national level took place with the 
Portuguese authorities, in particular in the framework of the new building in Lisbon. 
These included meetings with the Minister of Health, the Secretary of State for Maritime 
Affairs, the Head of Cabinet of the President of the Republic of Portugal, the President 
of the Lisbon Port Authority and the President of the IDT (the Portuguese Drug Addiction 
Institute). Mr Götz also made a presentation of the EMCDDA 2006 Annual Report in the 
context of its launch in Portugal. In addition to relations with the Portuguese authorities, 
notable events at national level included the visits to the Centre by: Ms Sabine Bätzing, 
the new Drug Commissioner of Germany; Mr John Mann, member of the UK House of 
Commons; the British Ambassador, Mr John Buck and a delegation from the UK national 
focal point; the Ambassador of Luxembourg in Lisbon, Mr Alain de Muyser; Mr Christian 
Schønau, the Permanent Secretary at the Danish Ministry of the Interior and Health, and 
the Danish member of the EMCDDA Management Board, Mr Mogens Jörgensen. The 
Director also invited the diplomatic corps based in Lisbon as well as several relevant 
Portuguese authorities to visit the Centre on the International day against drug abuse and 
illicit trafficking (26 June).
Other organisations and bodies 
The most important event in the context of ‘other organisations and bodies’ (Article12 
of the EMCDDA founding regulation) was a meeting with Mr. Antonio Maria Costa, 
Executive Director of UNODC, on 21 February in Vienna. 
Non-Community countries 
At the level of non-community countries (article 13 of the EMCDDA founding regulation), 
the most relevant events to report were in the framework of the cooperation with the 
Russian Federation. Meetings were held in Moscow with Mr Viktor Cherkesov, the 
Director of the Federal Service for Narcotics Traffic Control (FDCS) and with Mr Ruslan 
Halfin, Deputy Minister of Public Health and Social Development. A visit to the EMCDDA 
was made by a delegation of the FDCS, chaired by Mr Dmitry Kostennikov. An EU-Russia 
expert meeting on drug and drug addiction was also held in Warsaw. Other contacts 
included visits to the EMCDDA by the following: the Vice-Minister of Justice of Cuba, 
Ms Esther Zamora; a representative of the Australian Government, Ms Karen Price; the 
Ambassador of the Ukraine, Mr Rostyslav Tronenko; the Ambassador of Colombia, Mr 
Plinio Apuleyo Mendoza; a high-level delegation of five Portuguese-speaking countries 
(Angola, Brazil, Cape Verde, S. Tomé and Príncipe and Mozambique) and a delegation 
of the Turkish International Academy Against Drugs and Organised Crime (TADOC), 
which included representation from the Turkish national focal point. 
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Scientific Committee
Activities and results
A new EMCDDA Scientific Committee began work in 2006. It consists of one scientist per Member 
State and Norway, each nominated by their government. Many countries renewed the nomination of the 
previous member of the Scientific Committee whereas eight countries nominated new experts and the 
Czech Republic, Cyprus and Slovenia sent Scientific Committee members for the first time. Professor Henk 
Garretsen (NL) was elected chairperson and Professor Girts Brigis (LT) vice chairperson of the Committee. 
The Scientific Committee held two meetings during the year: 9–10 February and 4–5 December. 
One of the formal tasks of the Scientific Committee is to provide an opinion on the Centre’s work 
programmes. The opinion on the 2007–2009 work programme could only be obtained through a written 
procedure at the end of 2005. However, the three-year work programme was discussed in detail at the 
February meeting. The 2007 work programme was presented and debated in December 2006 and the 
Scientific Committee expressed a positive opinion.
The Scientific Committee regularly reviews the draft EMCDDA Annual report, Statistical bulletin and 
Selected issues and delivered many helpful comments and suggestions in 2006. For the first time, the 
Committee was also involved in the decision-making for the Selected issues for the next round of national 
reporting.
The recast of the EMCDDA Regulation provided a topical issue for the Scientific Committee during the 
year. The opinion, primarily expressed by the European Parliament, that the Committee should in the 
future consist of a limited number of independent experts met with considerable opposition. After the 
February meeting the Committee submitted a letter to the chairman of the Horizontal Working Party 
on Drugs, voicing arguments in favour of maintaining the representation of each Member State in the 
Scientific Committee. However, in the final recast which was approved by the end of the year, it was 
stated that the Scientific Committee ‘shall consist of at most fifteen well-known scientists appointed in view 
of their scientific excellence and their independence by the Management Board, following the publication 
of a call for expressions of interest in the Official Journal of the European Union’. In the December 
meeting, selection criteria and modalities for the nomination process were discussed. In anticipation of a 
subsequent decision of the Management Board, Dr. Anne-Marie Sindballe (DK) and Prof. Salme Ahlström 
(FI) were nominated for a working group to prepare draft guidelines for the selection and appointment of 
the new Scientific Committee.
No risk assessment of new synthetic substances was launched during the year. Instead, the revision of the 
Guidelines for risk assessment was taken forward by the ‘new drugs’ subcommittee and external experts. 
The Guidelines are planned to be ready for testing in the first half of 2007, in the case of an upcoming 
risk assessment. Individual members of the Scientific Committee supported and advised the EMCDDA 
throughout the year, e.g. with peer reviews of EMCDDA publications, such as the cannabis monograph 
and through participation in expert meetings.
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Chapter 1 
Characteristics and nature of the EMCDDA 
management and internal control systems 
The financial regulation applicable to the EMCDDA transposes integrally the text of the 
Commission framework Financial Regulation no. 2343/2002 (28). In accordance with 
this regulation, the EMCDDA has set internal procedures for budget execution and internal 
control, while defining and implementing a partially-decentralised management model. 
Operational and financial decisions required for the implementation of the EMCDDA work 
programme and budget have been decentralised by delegation to the relevant heads of 
the unit. The administrative unit provides the support to operational managers for financial 
management and ensures internal planning and monitoring, as well as the ex ante 
verification of transactions. These procedures have been codified and all the heads of unit 
and deputy authorising officers have received specific training and information on their 
role, duties and liability in accordance with the relevant provisions of the financial and staff 
regulations.
The key actors and steps of the EMCDDA procedures for budget execution can be 
summarised as follows:
• Project manager: initiation and operational input of the administrative and financial 
operations required to implement projects (e.g. technical specifications for tendering 
procedures, cost estimate, ‘certified correct’ sign-off for payments).
• Financial management team, financial helpdesk: preparation of the required 
administrative and contracting supporting documents with the input of the concerned project 
manager.
• Planning and evaluation team: checking of compliance with the adopted work programme 
and budget.
• Financial management team, SI2 initiating officers: operating the EMCDDA SI2 electronic 
management and accounting system to prepare the decision of the authorising officer. 
• Financial management team, verifying officer: ex ante verification. 
• Head of unit: authorisation of the required budgetary and legal operations for the 
execution of the concerned programme, acting as deputy authorising officer by delegation 
from the Director as EMCDDA authorising office; this authorisation must be within the limits 
of the appropriations earmarked for the operation under the adopted EMCDDA annual 
budget.
• Accountant: execution of the required financial transactions.
These procedures are consistent with the EMCDDA project-based working methods aimed at 
matching activities and resources management, in accordance with the ABM-ABB principles. 
In this context, the Centre has established procedures for planning, monitoring and reporting 
with a clear indication of the actors involved, their role and responsibilities.
A new Operating framework for the Reitox system was adopted by the EMCDDA 
Management Board in January 2003. A new grant agreement model was introduced for the 
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annual co-financing of the activities of the Reitox national focal points which fully complies 
with the relevant provisions of the financial regulation. This agreement requires that an 
external annual audit be carried out by an independent body or expert officially authorised 
to carry out audits of accounts in order to certify that the financial documents submitted 
to the EMCDDA by the beneficiary comply with the financial provisions of the agreement, 
that the costs declared are the actual costs, and that all receipts have been declared. The 
European Court of Auditors and the European Anti-Fraud Office (OLAF) enjoy the right of 
access for the purposes of checks and audits.
Taking into account the EMCDDA’s current activity and structure and considering the 
budgetary constraints, the EMCDDA relies on the European Commission’s Internal Audit 
Service (IAS) for its internal audit, in accordance with the applicable financial regulation.
Key features of the EMCDDA’s partially decentralised management model
Actors/level of operations Role/operations
Decentralised level (operational and 
technical units)
Operational initiative/input and 
operational and financial decisions by 
delegation in order to implement the work 
programme (WP) and budget
Central level (Directorate and 
administrative units)
Coordination and management of 
executive planning, monitoring, reporting 
and assessment of the implementation of 
the WP and budget
Administrative and financial 
support, management and control of 
implementation
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Key features of the process for the execution of the EMCDDA work programme and 
budget
Level of operations Actors Role/operations
Decentralised level 
(operational and technical 
units)
Concerned project manager 
and Head of unit
Initiative and operational 
input for the operations 
required to implement 
projects
Central level (administrative 
unit)
Planning and evaluation 
team
Check compliance of 
operations with adopted 
WP and budget plan. 
Budgetary appropriations 
to be committed are set 
aside
Human resources 
management team
Define rights and check 
compliance with staff 
regulations for missions and 
staff-related expenditure
Financial management 
team
Prepare the required 
administrative and legal 
supporting documents and 
control compliance with 
applicable regulations. 
Process and control the 
required SI2 operations
Decentralised level 
(operational and technical 
units)
Head of unit/deputy 
authorising officer
Authorise budgetary and 
legal commitments and 
payments (and recovery 
orders)
Central level (administrative 
unit)
Accountant Execute and record 
financial transactions
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Chapter 2 
Assessment and improvement of management and 
internal control systems
The following measures were implemented by the EMCDDA in 2006 in order to improve 
its management and internal control systems. These follow up the observations and 
recommendations expressed by the European Court of Auditors and the EU Budget Authority 
within the framework of the discharge given for the 2005 financial exercise. They also reflect 
the results of the audit of the EMCDDA internal control system carried out by the IAS in 
2005:
• Adoption of the budget/work programme (WP) in the year N-1.
• Tendering and contracting procedures for the execution of the budget/WP to be launched 
by 15th July.
• Procedures for the organisation of meetings to be launched by 30th September.
• Six-months assessment of the budget execution with any proposals for de-commitment and 
or re-assignment of resources to be discussed at the Heads of unit meeting.
• Automatic de-commitment and re-assignment of appropriations committed for meetings and 
missions.
• Ensure quick and effective re-assignment of unused appropriations.
• Define a regular ceiling for advance payment for staff missions (50% of the subsistence 
allowance plus maximum refund for hotel expenses).
• Apply as a rule the pre-paid ticket system for participants in EMCDDA meetings entitled to 
refunding of travel expenses.
• Increase and improve the capacity for support of the execution of the budget/work 
programme at the level of the deputy authorising officers/project managers.
• Reinforcement of the reporting system by producing monthly updated tables of budget 
execution available on a common drive of the EMCDDA intranet.
• Improvement of the planning of calls for tenders, to keep emergency cases to a minimum.
• More structured use of framework contracts.
• Implementation of a new contracts database linked to SI2, to allow a better reporting 
system.
• Appointment of members of the tender opening and evaluation committees according to the 
new financial implementing rules.
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• Internal guidelines/tools have been developed for the assessment of exclusion, selection and award 
criteria, to ensure that evaluation of tenders is carried out in a more consistent manner.
• A double signature system for the management of the Centre’s bank accounts has been adopted in 
order to ensure the proper segregation of duties in the financial circuits.
• The charters of the EMCDDA authorising officers by delegation and sub-delegation were adopted, 
communicated to and counter-signed by the concerned actors between July and September 2006 in 
order to ensure the proper accountability of the deputy authorising officers by delegation.
• The authorising officer of the EMCDDA decided to limit the delegation to the deputy authorising 
officers to a maximum amount of 130,000 euros per operation/transaction.
• An automatic link between budgetary accounting and general accounting has been created. 
Reconciliation between the accounts and the inventory is scheduled for the month of January following 
the end of the relevant financial year. In addition, in July 2006 the EMCDDA completed a physical 
check of its inventory items. The results of this check were entered into a specific computer system.
• The decision has been taken by the Director to delegate to EMCDDA heads of unit the powers of 
the Appointing Authority (AA) relating to the authorisation of staff leave and to staff appraisals. A 
decision was adopted in July 2006 to revise the current system, delegating in a more systematic way 
some of the powers of the AA relating to the recruitment process and the management of staff rights 
and obligations. Furthermore, following the conclusion of a specific service level agreement, the 
European Commission’s PMO has been empowered by delegation to prepare, check and process the 
payment of the remuneration of EMCDDA staff.
• The Director’s decisions, as EMCDDA authorising officer and appointing authority, are now 
countersigned/signed off by the head of administration when these decisions concern the Director 
himself.
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Declaration of assurance of the authorising officer
I, the undersigned, Director of the European Monitoring Centre for Drugs and Drugs 
Addiction, 
in my capacity as authorising officer: 
• declare that the information contained in this report gives a true and fair view (*).
• state that I have reasonable assurance that the resources assigned to the activities 
described in this report have been used for their intended purpose and in accordance with 
the principles of sound financial management, and that the control procedures put in place 
give the necessary guarantees concerning the legality and regularity of the underlying 
transactions.
This reasonable assurance is based on my own judgment and on the information at my 
disposal, such as the results of the self-assessment, ex post controls, the observations of the 
Internal Audit Service and the lessons learnt from the reports of the Court of Auditors for 
years prior to the year of this declaration.
• confirm that I am not aware of anything not reported here which could harm the interests 
of the Agency and the institutions in general.
Done in Lisbon, on 14 May 2007
(*) True and fair in this context means a reliable, complete and correct view on the state of affairs in the 
service.
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Annex 2 
Breakdown of EMCDDA staff in 2006
EMCDDA officials and temporary staff
AT 0
BE 3
BG 1
CY 0
CZ 0
DE 8
DK 1
EE 0
EL 0
ES 3
FI 0
FR 3
HU 0
IE 1
IT 4
LT 0
LU 1
LV 0
MT 0
NL 1
NO 1
PO 0
PT 3
RO 0
SE 1
SK 1
SL 0
UK 7
AD 16
AD 15
AD 14
 Temporary agents  1
 Subtotal   1
AD 13
AD 12
 Temporary agents  4
 Subtotal   4
AD 11
 Officials   3
 Temporary agents  7
 Subtotal   10
AD 10 
 Temporary agents  5
 Subtotal   5
AD 9 
 Temporary agents  6
 Subtotal   6
AD 8 
 Temporary agents  3
 Subtotal   3
AD 7 
 Temporary agents  2
 Subtotal   2
AD 6 
 Temporary agents  5
 Subtotal   5
AD 5 
 Temporary agents  3
 Subtotal   3
Total female   15
Total male    24
TOTAL AD    39
Category and grade Total by 
category and grade
Nationalities
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LV 0
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NL 1
NO 1
PO 0
PT 3
RO 0
SE 1
SK 1
SL 0
UK 7
AD 16
AD 15
AD 14
 Temporary agents  1
 Subtotal   1
AD 13
AD 12
 Temporary agents  4
 Subtotal   4
AD 11
 Officials   3
 Temporary agents  7
 Subtotal   10
AD 10 
 Temporary agents  5
 Subtotal   5
AD 9 
 Temporary agents  6
 Subtotal   6
AD 8 
 Temporary agents  3
 Subtotal   3
AD 7 
 Temporary agents  2
 Subtotal   2
AD 6 
 Temporary agents  5
 Subtotal   5
AD 5 
 Temporary agents  3
 Subtotal   3
Total female   15
Total male    24
TOTAL AD    39
Category and grade Total by 
category and grade
Nationalities
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AT 0
BE 6
BG 0
CY 0
CZ 0
DE 1
DK 0
EE 0
EL 2
ES 2
FI 0
FR 4
HU 0
IE 1
IT 1
LT 0
LU 1
LV 0
MT 0
NL 0
NO 0
PO 1
PT 9
RO 0
SE 0
SK 0
SL 0
UK 1
AST 11
 Officials   1
 Subtotal   1
AST 10
 Subtotal   0
AST 9
 Subtotal   0
AST 8
 Temporary agents  1
 Subtotal   1
AST 7
 Officials   1 
 Temporary agents  4
 Subtotal   5
AST 6
 Temporary agents  4
 Subtotal   4
AST 5 
 Temporary agents  2
 Subtotal   2
AST 4 
 Temporary agents  4
 Subtotal   4
AST 3 
 Officials   1
 Temporary agents  10
 Subtotal   11
AST 2 
 Subtotal   0
AST 1 
 Temporary agents  1
 Subtotal   1
Total female   18
Total male    11
TOTAL AST   29
Category and grade Total by 
category and grade Nationalities
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AT 0
BE 6
BG 0
CY 0
CZ 0
DE 1
DK 0
EE 0
EL 2
ES 2
FI 0
FR 4
HU 0
IE 1
IT 1
LT 0
LU 1
LV 0
MT 0
NL 0
NO 0
PO 1
PT 9
RO 0
SE 0
SK 0
SL 0
UK 1
AST 11
 Officials   1
 Subtotal   1
AST 10
 Subtotal   0
AST 9
 Subtotal   0
AST 8
 Temporary agents  1
 Subtotal   1
AST 7
 Officials   1 
 Temporary agents  4
 Subtotal   5
AST 6
 Temporary agents  4
 Subtotal   4
AST 5 
 Temporary agents  2
 Subtotal   2
AST 4 
 Temporary agents  4
 Subtotal   4
AST 3 
 Officials   1
 Temporary agents  10
 Subtotal   11
AST 2 
 Subtotal   0
AST 1 
 Temporary agents  1
 Subtotal   1
Total female   18
Total male    11
TOTAL AST   29
Category and grade Total by 
category and grade Nationalities
A II 
 Subtotal   0
A III
 Subtotal   0
Total female   0
Total male    0
TOTAL AUXILIARY AGENTS  0
Category and grade Total by 
category and grade
EMCDDA auxiliary staff
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EMCDDA contractual staff
AT 0
BE 2
BG 0
CY 0
CZ 0
DE 0
DK 0
EE 0
EL 0
ES 0
FI 0
FR 1
HU 0
IE 0
IT 1
LT 0
LU 0
LV 0
MT 0
NL 0
NO 0
PO 0
PT 13
RO 0
SE 0
SK 0
SL 0
UK 0
GF I
 Subtotal   2
GF II
 Subtotal   11
GF III
 Subtotal   6
GF IV
 Subtotal   0
Total female   12
Total male    7
TOTAL CONTRACTUAL STAFF  19
Category and grade Total by 
category and grade Nationalities
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UK 0
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 Subtotal   11
GF III
 Subtotal   6
GF IV
 Subtotal   0
Total female   12
Total male    7
TOTAL CONTRACTUAL STAFF  19
Category and grade Total by 
category and grade Nationalities
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GF III
 Subtotal   6
GF IV
 Subtotal   0
Total female   12
Total male    7
TOTAL CONTRACTUAL STAFF  19
Category and grade Total by 
category and grade Nationalities
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Outputs
Publications
Annual report 2006: the state of the drugs problem in Europe
A yearly overview of the drug phenomenon in Europe.
Available in 23 languages — all EU official languages (except Maltese), Bulgarian, Romanian, 
Turkish and Norwegian.
Cat. no.: TD-AC-06-001-BG/CS/DA/DE/EN/ES/ET/FI/FR/GR/HU/IT/LT/LV/NL/NO/PL/PT/
RO/SK/SL/SV/TR-C
http://www.emcdda.europa.eu/?nnodeid=419
Also available as a 23-language website with additional explanatory material, graphics and 
data sources (http://ar2006.emcdda.europa.eu/) 
Annual report 2006: selected issues
Three in-depth reviews that accompany the report: European drug policies — extended beyond 
illicit drugs?, A gender perspective on drug use and responding to drug problems, Developments 
in drug use within recreational settings
Available in EN.
Cat. no.: TD-AF-06-001-EN-C
Also available as a website (http://issues06.emcdda.europa.eu/) 
General report of activities 2006
A detailed progress report of the EMCDDA’s activities over a 12-month period.
Available in EN.
(http://www.emcdda.europa.eu/?nnodeid=426)
Drugnet Europe 
The EMCDDA’s newsletter provides regular and succinct information on the Centre’s activities to 
a broad readership.
4 editions (53, 54, 55 and 56) 
Available in EN. 
(http://www.emcdda.europa.eu/?nnodeid=411)
Thematic papers
Hallucinogenic mushrooms: an emerging trend case study
Available in EN. 
(http://www.emcdda.europa.eu/?nnodeid=7079)
Marketing brochures
Presentation flyer
’About the EMCDDA’ (November 2006) BG/RO/TR
(http://www.emcdda.europa.eu/?nnodeid=437)
Leaflets
‘Monitoring new drugs’ (February 2006) 
Available in EN.
(http://www.emcdda.europa.eu/?nnodeid=17869)
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Media products 
News releases 
7 news releases
No 1 — Germany’s new national drugs coordinator visits Lisbon
‘Sabine Bätzing briefed on EMCDDA’s work and findings’
(27.2.2006) DE/EN/PT
No 2 — 26 June: International day against drugs
‘New trend in magic mushrooms reflects young Europeans’ appetite for intense experiences’
(26.6.2006) DE/EN/FR/PT
No 3 — Latest on the drug problem across Europe 
‘2006 Annual report from the EU drugs agency’ 
(6.11.2006)
ES/CS/DA/DE/ET/EL/EN/FR/IT/LV/LT/HU/NL/PL/PT/SK/SL/FI/SV/NO/BG/RO/TR/
No 3a — Vice-President Frattini visits EU drugs agency in Lisbon 
‘Up-to-date intelligence crucial to curbing Europe’s drug problems’
(21.11.2006) EN/IT/PT
2006 Annual report information package 
A list of products and services 
EN
Drugs in Europe — facts and figures
(23.11.2006) ES/CS/DA/DE/ET/EL/EN/FR/IT/LV/LT/HU/NL/PL/PT/SK/SL/FI/SV/NO/BG/RO/TR
Message from Wolfgang Goetz, director of the EMCDDA
(23.11.2006) ES/CS/DA/DE/ET/EL/EN/FR/IT/LV/LT/HU/NL/PL/PT/SK/SL/FI/SV/NO/BG/RO/TR
No 4 — Annual report 2006: Drug prices down, seizures up
‘Drugs in Europe now cheaper than ever before’
(23.11.2006) ES/CS/DA/DE/ET/EL/EN/FR/IT/LV/LT/HU/NL/PL/PT/SK/SL/FI/SV/NO/BG/RO/TR
No 5 — Annual report 2006: A gender perspective on drug use
‘Drug treatment services for women still limited in Europe’
(23.11.2006) ES/CS/DA/DE/ET/EL/EN/FR/IT/LV/LT/HU/NL/PL/PT/SK/SL/FI/SV/NO/BG/RO/TR 
No 6 — Annual report 2006: Drug use in recreational settings
‘Surveys find club-goers over 10 times more likely to have tried stimulant drugs’
(23.11.2006) ES/CS/DA/DE/ET/EL/EN/FR/IT/LV/LT/HU/NL/PL/PT/SK/SL/FI/SV/NO/BG/RO/TR
No 7 — EU drugs agency management board elections
‘Board members re-elect Marcel Reimen as EMCDDA Chairman’
(13.12.2006) DE/EN/FR/PT
Audio (MP3) files
17 Audio clips (MP3 files) of comments from the EMCDDA Director on the 2006 Annual report
http://www.emcdda.europa.eu/?nnodeid=23150 
Fact sheets 
4 Fact sheets 
Available in EN. 
Fact sheet 1: Quotebank 2005
Fact sheet 2: Profile of EMCDDA Director Wolfgang Götz
Fact sheet 3: EU drugs agency formalises relations with Publications Office
Fact sheet 4: President of the European Commission at EMCDDA
http://www.emcdda.europa.eu/?nnodeid=24028
Press reviews
4 quarterly press reviews
1 ad hoc press review for International day against drug abuse and illicit trafficking (26 June)
1 six-volume 1,700-page Annual report press review
EMCDDA thematic papers 
Hallucinogenic mushrooms: an emerging trend case study.
Epidemiological evidence on Drug-Facilitated Sexual Assault (DFSA) for Parliamentary Assembly, 
Council of Europe, Committee on Equal Opportunities for Women and Men.
Paper on key topics related to illegal drug use for DG Sanco Working Party on Lifestyle, Specific 
and Deprived Population Groups.
ELDD topic overviews
Hallucinogenic mushrooms (28/4/06)
Drug testing in the workplace (11/5/06)
Drugs and driving (20/7/06)
Personal possession of cannabis (14/9/06)
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Websites
EMCDDA public website
The gateway to drug information in Europe. Ongoing updates and content development.
http://www.emcdda.europa.eu 
Annual report 2006
The multilingual Annual report website offers full online version of the report in 23 languages 
and press materials.
http://ar2006.emcdda.europa.eu/
Statistical bulletin 2006
The bulletin is a companion publication to the EMCDDA Annual report and presents the full 
set of source tables on which the statistical analysis in the annual report is based. It also 
provides further detail on the methodology used and over 100 additional statistical graphs.
http://stats06.emcdda.europa.eu/
Country situation summaries
Country situation summaries are available for the EU Member States and Norway as well 
as several countries of the former Soviet Union. They offer a rich pool of national drug 
data in Europe. Their main purpose is to provide brief synopses of up-to-date national data 
and trends. They also include selected links to other national information sources. They are 
updated once a year.
http://profiles.emcdda.europa.eu/?nnodeid=1966
Drug treatment overviews
The ‘Drug treatment overviews’ describe the national drug treatment systems operating in the 
25 EU Member States, Bulgaria, Romania and Norway.
http://www.emcdda.europa.eu/?nnodeid=7613
European legal database on drugs
The European legal database on drugs (ELDD) is the EMCDDA’s online database of 
information on European drugs-related legislation for the EU Member States and Norway. 
Ongoing updates and content development.
http://eldd.emcdda.europa.eu
Evaluation instruments bank
The EMCDDA’s Evaluation instruments bank (EIB) is a document archive of tools created 
to encourage evaluation using reliable methods, and to help to standardise these tools at 
European level. The Instruments Bank contains tools for evaluating both prevention and 
treatment programmes. Ongoing updates and content development.
http://eib.emcdda.europa.eu
Exchange on drug demand reduction action
The Exchange on drug demand reduction action (EDDRA) is a multilingual online information 
system and data-collection tool on best practice in responding to drug use in the European 
Union. Ongoing updates and content development.
http://www.emcdda.europa.eu/?nnodeid=1580
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Contributions to the first European Commission progress review of the EU action plan 
(2006)
Thematic paper on the objective 10 of the EUAP 2005-2008: ‘Improve methods for early 
detection of risk factors and early intervention’
Thematic paper on the objective 11 of the EUAP 2005-2008: ‘Ensure the availability of and 
access to targeted and diversified treatment and rehabilitation programmes’
Thematic paper on the objective 15 of the EUAP 2005-2008: ‘Availability and access to harm 
reduction services’
Thematic paper on the objective 16 of the EUAP 2005-2008: ‘Prevention of the spread of HIV/
AIDS, hepatitis C, other blood borne infections and diseases’
Thematic paper on the objective 17 of the EUAP 2005-2008: ‘Reduction of drug-related deaths’
Thematic paper on the objective 32 of the EUAP 2005-2008: ‘’Provide the necessary technical 
and other assistance to the candidate and stabilisation and association process countries’
Thematic paper on the objective 39 of the EUAP 2005-2008: ‘provide reliable and comparable 
data on the key epidemiological indicators’
Thematic paper on the objective 40.1 of the EUAP 2005-2008: ‘provide reliable information on 
the drug situation’
Thematic paper on the objective 41.1 of the EUAP 2005-2008: ‘develop clear information on 
emerging trends and patterns of drug use and drug markets’
Technical reports
Domingo Salvany, A. (2006), ‘Translate and adapt scales for problematic use, abuse and 
dependence of cannabis to Spanish and Catalan (for their eventual subsequent field testing in 
2006 Spanish secondary school surveys ESTUDES)’, EMCDDA, Lisbon.
Hibell, B. (2006), ‘The ESPAD 2007 Questionnaire Test’, EMCDDA, Lisbon.  
King, L. A., Sedefov, R. (2006), ‘Early-warning system on new psychoactive substances 
– Operating guidelines’, EMCDDA, Lisbon.
Kontogeorgiou, K., Wiessing, L. et al (2006), Draft protocol for the implementation of the 
EMCDDA key Indicator Drug-related infectious diseases (DRID), Report CT.04.P1.337, EMCDDA, 
Lisbon, 6 October 2006.
Ncube, F. (2006), ‘Pilot project to assess the feasibility of laboratory surveillance of hepatitis C 
virus in young people in Europe’, EMCDDA, Lisbon.
Frost, N., Pina, F., Tempalski, B. (2006), ‘Geographical Information Systems and Spatial 
Epidemiology in the European Region: problems and potential benefits from geocoded health 
data’, EMCDDA, Lisbon.
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Klempova, D. and Vicente, J. (2006), ‘Summary: data collection on the intensive forms of 
drug use measurement in the general population surveys. Adolescent population surveys: 
questions related to intensive forms of drug use and adult population surveys: questions 
related to intensive forms of drug use’, EMCDDA, Lisbon.
Vicente, J. (2006), ‘Proposal to update the EMCDDA protocol for Drug-related deaths (DRD 
Standard Protocol, Version 3.1) according to WHO updated guidelines to codify drug-
related deaths based on ICD-10’, EMCDDA, Lisbon.
Vicente, J. and Matias, J. (2006), Draft report on Toxicological field trial; EMCDDA, Lisbon, 
November 2006.
Articles
Articles in journals
Aceijas, C., Friedman, S. R., Cooper, H. L. F., Wiessing, L., Stimson, G. V., Hickman, M. 
(2006), ‘Estimates of injecting drug users at the national and local level in developing and 
transitional countries, and gender and age distribution’, Sexually Transmitted Infections 
2006:82(Suppl III):iii10–iii17.
Ballotta, D. and Bergeron, H. (2006), ‘What drug policies cost. Does Europe know how 
much it is spending to face the drugs phenomenon?’, Addiction, Volume 101, number 3 
March 2006, pp. 339–340.
Bargagli, A. M., Hickman, M., Davoli, M., Peducci, C. A., Schifano, P., Buster, M., Brugal, 
T., Vicente, J. (2006), ‘Drug-related mortality and its impact on adult mortality in eight 
European countries’, Cosmo European Group. The European Journal of Public Health 2006 
16(2), pp.198–202.
García-Romero, A., Royuela-Morales, L. (2006), ‘Evaluación del impacto socioeconómico de 
la investigación en enfermería’. Enferm.Clin.2006;16(3), pp.148–54.
Klempova, D., Okruhlica, L. (2006), ‘No intrauterine growth retardation in babies of 
mothers stabilized on methadone before conception and throughout their pregnancies. 
Heroin Add & Rel Clin Probl 2006; 8(1): 25-30.
Lopez, D., Sansfaçon, D. (2005), ‘Dommages sociaux lies à l’usage de drogues: focus sur 
les relations et difficultés familiales’, Revue toxibase n°20 – 4e trimestre 2005.
Montanari, L. (2006), ‘I pazienti in trattamento per uso di droga in Europa: tendenze 
recenti’, ITACA, Cooperazione sociale e inserimenti lavorativi, 2006: 14-25.
Montanari, L. and Vicente, J. (2006), ‘Il consumo problematico di cocaina in Europa: 
dati recenti sui pazienti in trattamento, in: Cocaina, Manuale di Aggiornamento tecnico-
scientifico, gennaio 2006: 27–36. 
Smit, F., Van Laar, M. and Wiessing, L. (2006), ‘Estimating problem drug use prevalence 
at national level: Comparison of three methods’, Drugs: education, prevention and policy, 
Vol.13, No. 2, April 2006, pp.109–120.
Vaissade, L.. and Lopez, D. (2006), ‘Recueil mensuel dans les consultations cannabis’, in: 
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‘Premier bilan des consultations cannabis’, Tendances n°50, septembre 2006, OFDT.
Wiessing, L. and Nardone, A. (2006), ‘Ongoing HIV and viral hepatitis infections in IDUs 
across the EU, 2001–2005’, Eurosurveillance 2006: 11(11); 23 Nov 2006. http://www.
eurosurveillance.org/ew/2006/061123.asp#2
Book chapters and other articles
Ballotta, D. (2006), ‘Actitudes internacionales sobre el cannabis y sus aplicaciones en la Union 
Europeia’, in: Cannabis: Salud legisaltion y politica de intervention, Instituto Internacional de 
Sociología Juridica de Oñati, Dykinson, 2006.
Burkhart, G. (2006), ‘Prevención selectiva en la Unión Europea y Noruega’, in: Pantoja, L. (ed.) 
(2006), Prevención selectiva del consumo de drogas en menores vulnerables, Universidad de 
Deusto. Série Drogodependencias, vol. 17, pp. 59–98.
Martel, C. (2006), ‘La lutte contre le phénomène des drogues’, in: Les défis d’une adhésion de 
la Turquie à l’Union européenne, édition Bruylant, Bruxelles 2006, pp. 105–124. 
Nilson, M., Fridell, M., Griffiths, P. (2006), ‘Co-morbidity – developing a European perspective’, 
in: Baldaccino, A., Corkery, J. (eds.) (2006), Co-morbidity. Perspectives across Europe. 
Monograph Series No 4. European Collaborating Centres in Addiction Studies (ECCAS), 
London, pp 351–363.
Prieto, L. (2006), ‘Economic Implications of Drug Therapies – The European Perspective’, in: 
Suchttherapie, Issue 04, Volume 7, December 2006.
Published abstracts and oral presentations at scientific conferences and meetings
Ballotta, D., ‘Cocaine in the EU’, National Drug Coordinators, Innsbruck, 16–17 February 
2006.
Ballotta, D., ‘Drug demand reduction in Europe’, EU/LAC High Level meeting, Vienna, 6–7 
March 2006.
Ballotta, D., ‘The drugs situation in the EU’, Troika EU/Western Balkans, Brussels, 10 May 2006.
Ballotta, D., ‘Treating addicts in prison’, Horizontal Working Party on Drugs, Brussels, 11 May 
2006.
Ballotta, D., ‘Social reintegration in the EU’, Horizontal Working Party on Drugs, Brussels, 7 June 
2006.
Ballotta, D., ‘European trends in substitution treatment and harm reduction’, 2nd Ministerial 
Conference ‘Drug Routes from Afghanistan’ (Paris 2 — Moscow 1), Moscow, 27 June 2006.
Ballotta, D., ‘Demand reduction efforts in the EU’, High Level Specialised Dialogue on Drugs 
between the EU and the Andean Community, Brussels, 27 September 2006.
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Ballotta, D., ‘EMCDDA research coordination’, Horizontal Working Party on Drugs, Brussels, 31 October 
2006.
Ballotta, D., ‘Hablemos de cannabis’, Bilbao, 16 November 2006.
Ballotta, D., ‘Annual Report 2006’, Horizontal Working Party on Drugs, Brussels, 22 November 2006.
Burkhart, G., ‘Selective prevention’, International Prevention Conference, Padova,10 February 2006.
Burkhart, G., ‘State of the art of prevention effectiveness’, VIII Reunión Nacional de Drogodependencias, 
Valencia, 11 February 2006.
Burkhart, G., ‘School-based prevention in Europe’, Pompidou Group meeting: Prevention among children 
of Drug users, Zagreb, 20-22 March 2006. 
Burkhart, G., ‘Logic models in prevention’, at the Re-Ligo, Convegno nazionale, Milan, 30 March 2006.
Burkhart, G., ‘State of the art of selective prevention and indicated prevention’, German-Polish Congress 
‘Grenzenlos dicht…?!’, Ravensburg17–18 May 2006.
Burkhart, G., ‘State of the art of selective prevention’, final meeting of the Dutch-German interregio 
project on Early Intervention and Self-Help (Alcohol and Cannabis), Brussels, 22 June 2006.
Burkhart, G., ‘State of prevention in recreational settings’, Club Health 2006 conference in Piran, 20–22 
September 2006.
Burkhart, G., Training Seminar (full day) on models, theories, and evaluation of prevention in the course 
‘Formación continua en prevención do consumo de alcohol e outras drogas’, Santiago de Compostela, 
27 September 2006.
Burkhart, G., ‘State of family-based prevention’, Seminar ‘Famílias — Novas estratégias Preventivas’, 
Coimbra 24 November 2006.
Goosdeel, A., ‘The EMCDDA and the Reitox network’, Meeting at the Federal Service of the Russian 
Federation for Drug Trafficking Control, Moscow, 23–26 January 2006.
Goosdeel, A., Hedrich D., ‘Outreach work and data collection: the European experience’. TAIEX meeting 
- Expert mobilisation on street work programmes, Nicosia, 20–22 February 2006.
Goosdeel, A., ‘The EMCDDA and the Western Balkans, perspectives for cooperation’, Conference 
organised by the Greek Ministry of Foreign Affairs and the Andreas Papandreou Foundation on ‘The 
problem of illegal drugs in the Balkans and the Contribution of the Balkan Countries and the International 
Community in Addressing the Problem’, Athens, 31 March 2006.
Goosdeel, A., ‘Grant agreements management: general introduction’, Reitox Academy, Larnaca, 29–30 
June 2006.
Goosdeel, A., ‘The EMCDDA and the Reitox network, data collection and exchanges with non-EU 
Member States’, European Union Agencies meeting : ‘Enlargement of Data Collection and Networks to 
Candidate and to Third Countries’, Lisbon, 6 October 2006.
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Goosdeel, A., ‘The European data collection system on drugs’ and ‘Lessons learned from 
National Focal Point building in EU Member States and in candidate countries’, Presentation at 
CICAD-OAS, Washington, 30–31 October 2006.
Goosdeel, A., ‘The lessons learned from National Focal Point building in EU Member States 
and in candidate countries’, Joint CICAD-UNODC-EMCDDA meeting on the establishment and 
assessment of Drugs Monitoring Centres‘, Lisbon, 15 November 2006.
Goosdeel, A., ‘Annual report on the drug situation in Europe in 2006 — selected highlights’, 
Athens, 23 November 2006.
Goosdeel, A., ‘Drugs observatories: objectives and activities’, Kiev, 7 December 2006.
Griffiths, P., ‘Overview drug situation in Europe’, Latin America and the Caribbean meeting and 
Horizontal Drugs Group, Brussels, 9–10 January 2006.
Griffiths, P., ‘Cocaine problem in Europe’, Dialogue on shared responsibility and the global 
problem of illicit drugs’, London, 2 November 2006.
Griffiths, P., ‘Annual report on the drug situation in Europe in 2006 – selected highlights’, 
Brussels, 22–23 November 2006.
Griffiths, P., ‘HIV and injecting drug use in the European Union – available data, knowledge 
gaps and research needs’, Horizontal Working Party on Drugs, Brussels, 19 December 2006.
Hedrich, D., ‘Supervised Drug Consumption Rooms: Objectives and Outcomes’, Seminário 
Bioética e Comportamentos Aditivos: as Salas de Injecção Assistida, Aula Magna da Faculdade 
de Medicina, Porto, 20 January 2006. 
Hedrich, D. and David, A., ‘Hepatitis C strategies and prevention initiatives for drug users in 
the EU Member States, Hepatitis C and active drug use: from awareness to action’, CEE-HRN, 
Vilnius, 10–11 March 2006. 
Hedrich, D., ‘Improving data collection on responses to drug-related harm in Europe ‘, 
Correlation Network Conference, Krakow, 16 March 2006. 
Hedrich, D., ‘Jahresbericht 2005 über den Stand der Drogenproblematik in Europa –Überblick 
der wichtigsten Ergebnisse‘, Visit of Delegation by BKA (Germany), Lisbon, 2 March 2006. 
Hedrich, D., Carpentier, C., Merino, P. P. and Wiessing, L., ‘Drug users in EU prisons 
– situation and responses, all on drugs, public health and prisons’, International knowledge and 
experiences, Portuguese situation, SOMA, Lisbon, 9–10 May 2006. 
Hedrich, D., ‘Scenari europei della reduzione del danno. Acquisizioni, validazioni, valutazioni, 
linee guida’, La Riduzione del Danno in Europa e in Italia - Seminario da ASL 5, Turin, 12 
October 2006. 
Hedrich, D., ‘Trends in responses to infectious diseases and drug-related deaths in EU Member 
States’, Launch of the Annual Report on the state of the drugs problem in Europe - Ministry of 
Social Affairs, Tallinn, 23 November 2006. 
Hedrich, D., ‘Treatment and harm reduction responses to drug problems — the situation in the EU 
countries’, EU-Russia Expert Meeting, Warsaw, 13–14 November 2006. 
Hedrich, D., ‘Treatment and harm reduction responses to drug problems - the situation in the EU 
countries and Norway’, Visit of Norwegian Outreach Workers, Lisbon, 29 November 2006. 
Hedrich, D., ‘Prevention of acute drug-related deaths: Information update’, EMCDDA expert group 
meeting on key indicator DRD and mortality, Lisbon, 16–17 November 2006.
Hillebrand, J., ‘The European Drug Information Network – achievement and challenges. The EU – Russia 
Expert Meeting on Drugs and Drug Addiction’, Warsaw, 12–14 November 2006.
Hillebrand, J., ‘Magic mushrooms — an emerging case trend study’, Club Health Conference, Piran, 
Slovenia, 20–23 September 2006.
Hillebrand, J., ‘Drug prevalence and prevention in dance music settings in the EU’, Regional Prevention 
action meeting, Venice, 24 November 2006.
Hillebrand, J., ‘EDDRA in the context of evaluation practices’, Sistemas de evaluacion en las 
intervenciones en drogodependencias, Summer University, Santander, 10–11 July 2006.
Hillebrand, J., ‘Main findings — Annual report 2006’, Sofia, 23 November 2006.
Hillebrand, J., ‘Hallucinogenic mushrooms: an emerging trend case study’, Annual Early Warning 
System Meeting, Lisbon, 15–16 June 2006.
Hughes, B., ‘The European legislation on drugs and driving’, Road Traffic and Drugs Conference, 
Pompidou Group of Council of Europe, Strasbourg, 10 July 2006.
Hughes, B., ‘The European legislation on drugs and driving’, Working Group on Research Standards on 
Drugs and Driving, Talloires, France, 8–12 September 2006.
Hughes, B., ‘Legal treatment alternatives to prison in the EU’, Seminar on Alternatives to Prison, Cyprus 
Anti-Drugs Council, Nicosia, 24 November 2006.
Klempova, D., ‘Amphetamine-type stimulants: Indicators of the scope of their use in the EU Member 
States, Candidate Countries and Norway. Possible connections with HIV epidemic’, Methamphetamine 
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Participation in conferences and technical meetings 
Participation in external scientific conferences and meetings
+ internal meetings (KI expert meetings, other experts meetings)
Date Venue Title Participants
Director
23–26 
January
Moscow Visit to the Federal Drugs Control 
Service of the Russian Federation
Policy makers
30–31 
January
Brussels Meeting at the European Parliament, 
Discharge 2004
Policy makers
15–17 
February
Innsbruck National Drug Coordinators meeting Policy makers
20–22 
February
Vienna Meeting with Mr Costa (UNODC) Policy makers
22–23 
February
Brussels Heads of Agencies meeting EU agencies
11–15 March Vienna 49th Session of the Commission on 
Narcotic Drugs
Policy makers
27–28 April Brussels Meetings with Messrs Schinas, 
Edwards, Veresies, Deprez and 
Lallemand
Policy makers
27–28 June Stockholm Visit to the European Centre for 
Disease Prevention and Control
Experts, policy 
makers
11–13 July Brussels COBU-COCOBU meeting in the 
European Parliament. Preparation of 
the Launch of the AR 2006.
Policy makers
20–21 
September
Brussels European Parliament, meetings with 
several MEPs
Policy makers
18–20 
October
Copenhagen Heads of Agencies meeting EU agencies
12–14 
November
Warsaw The EU-Russia expert meeting on drugs 
and drug addiction
Policy makers
21–24 
November
Brussels Launch of the Annual Report Policy makers
28–29 
November
Strasbourg 58th meeting of Permanent 
Correspondents of the Pompidou 
Group 
Policy makers
External conferences involving presence of staff from different units
23–26 
January
Moscow Meeting at the Federal Service of the 
Russian Federation for Drug Trafficking 
Control
Politicians, experts
20 February Vienna Preparatory meeting for the UNODC 
Directors and review of MoU
Policy makers, 
experts
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9–10 March Vienna UNODC meeting: Methamphetamine 
abuse: health consequences, esp.HIV/
AIDS, and treatment’.
Experts, policy 
makers
13–17 March Vienna 49th session of the Commission on 
Narcotic Drugs
Policy makers
10–11 April The Hague Visit to Europol and discussion of 
collaboration with EMCDDA
Policy makers, 
experts
19–20 April Luxembourg Meeting with Sanco Policy makers, 
experts
11–12 May Brussels Horizontal Drugs Group Experts
22 May Helsinki Preparatory Meeting for ‘Moving 
Forward Together’ - Finish EU 
Presidency conference on Drugs
Policy 
makers,experts
19–23 June Ankara Re-assessment of the Turkish national 
focal point
Experts
10 July Brussels Horizontal Drugs Group meeting Experts
6–7 
September
Turku ‘Moving Forward Together’ - Finish EU 
Presidency conference on Drugs
Policy makers, 
experts
8–12 
September
Talloires - 
France
Workshop to develop standards for 
drugged driving research
Experts
21–23 
September
Lisbon 17th Annual Conference of the 
European Society for Social Drug 
Research
Scientists, 
researchers
Launch of the Annual report 
22–23 
November
Brussels Launch Annual Report Policy makers, 
media
22–23 
November
Brussels Launch Annual Report Policy makers, 
media
22–23 
November
Sofia Launch Annual Report Policy makers, 
media
22–23 
November
Nicosia Annual Report Launch, conference on 
Alternatives to Prison
Policy makers, 
media
22–23 
November
Tallinn Launch Annual Report Press, policy 
makers
22–26 
November
Vilnius Launch Annual Report Experts
5–7 
December
Riga Launch Annual Report Policy makers, 
media
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Programme EPI – Monitoring the drug situation - general
9–10 January Brussels Latin America and the Caribbean 
meeting and Horizontal Drugs Group
Policy makers, 
experts
6 April Edinburgh Meeting of research and information 
working group and UK focal point 
workshops
Experts, policy 
makers
15 May Paris Exchange of views on sexual 
assault linked to ‘date-rape drugs’, 
organized by the Committee on Equal 
Opportunities for women and men
Policy makers
18–20 June Zagreb Re-assessment mission in Croatia 
for the PHARE-EMCDDA project 
for preparation of Croatia for their 
participation in the EMCDDA
Experts
26 June Loures, 
Portugal
‘Dia Mundial da Luta Contra a Droga’ Policy makers
28 June Stockholm ECDC /EMCDDA meeting Experts
7 September London Medscreen ‘Masterclass’ Experts
5–7 October Ljubljana 9th European Conference on drugs 
and infections prevention in prisons
Experts
2 November London Dialogue on shared responsibility and 
the global problem of illicit drugs
Policy makers
27–28 
November
Strasbourg Pompidou Group Ministerial 
Conference
Policy makers, 
experts
19 December Brussels Horizontal Working Party on Drugs Policy makers, 
experts
Crime and supply 
21 February Vienna EUCPN Board meeting Policy makers, 
experts
23 February Brussels European Parliament / European 
Forum for Urban Security meeting on 
European policy on crime prevention
Policy makers
6 March Paris Pompidou Group preparatory meeting 
(editorial group) to 5th meeting of 
Criminal Justice Platform
Experts
27–28 April Strasbourg Pompidou Group 5th meeting of 
Criminal Justice Platform
Experts, policy 
makers,NGOs
13–14 June Lisbon Expert meeting: reviewing standard 
table 15 on contents of drug tablets
Experts
1–2 June Toulon Séminaire de travail européen restreint 
sur le thème: ‘Lutte contre le trafic de 
cocaïne’
Experts, policy 
makers
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12-14 June Sofia Annual meeting of the co-operation 
group of drug control services at 
European airports, Pompidou Group
Experts, policy 
makers
Health information networks (Sanco)
7–8 February Luxembourg Joint meeting of the network of WP 
leaders and Competent Authorities for 
Health, Sanco
Experts
18–20 
October
Stockholm 3rd Scientific Workshop of the 
Working Party on Information on 
Lifestyle, Specific and Deprived 
Population Groups  
Working Party on Information on 
Lifestyle, Specific and Deprived 
Population Groups
Public health 
scientists
18–19 May Luxembourg 3rd thematic meeting green paper on 
mental health, ‘Information, data and 
knowledge in mental health’,
Experts, policy 
makers, NGOs
Treatment demand
30 January Lisbon The Treatment Demand Indicator 
– Meeting on Prevalence Data with TDI
Experts
15–17 June (Blackpool) 
Manchester
T3E Seminar Experts
23 May Lisbon Taipas conference Experts
6–8 July London European Association of Addiction 
Therapy Annual Conference
Experts
14 September Perth Conference on co-morbidity Experts
25–26 
September
Lisbon The Treatment Demand Indicator 
(TDI) – 2006 Annual expert meeting 
and meeting with International 
organisations
Experts, 
international 
partners
Youth and ESPAD
31 March Lisbon Expert meeting: EMCDDA ESPAD 
Gender Group
Experts
19–20 June Helsinki ESPAD Project Meeting Experts 
Drug-related deaths
30 May Lisbon Visit of Turkish national focal point Experts
15 June Lisbon Visit of UK national focal point Experts
25–27 June Sofia Training workshop on drug-related 
deaths and mortality indicator 
Experts (NFP)
16–17 
November
Lisbon Key indicator ‘Drug-related deaths and 
mortality among drug users’ 2006 
Annual expert meeting
Experts
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Population surveys
3 April Lisbon Measurement of intensive forms of drug 
use. Concepts and possibilities
Experts
8–9 June Lisbon Expert meeting on key indicator 
‘prevalence and patterns of drug 
use among the general (Population 
Surveys) population 
Experts
15 June Lisbon Visit of UK national focal point Experts
30 May Lisbon Visit of Turkish national focal point Experts
28 September Madrid I reunion de validation de escalas de 
dependencia de cannabis en estudes 
2006
Experts
Infectious diseases
1–2 February Brussels Sixth Meeting of the ‘HIV/AIDS Think 
Tank’, DG Health and Consumer 
Protection
Policy makers, 
experts
7 February Lisbon Meeting with the Portuguese AIDS 
coordinator and representative of 
national AIDS committee
Experts
8 February Oeiras Meeting with infectious diseases 
modelling team at Gulbenkian Institute 
for Science, Oeiras
Experts
22–24 March Copenhagen Joint mapping meeting of the HIV/
AIDS data collection within the WHO 
European region.
Policy makers, 
experts
24 March Rome Conference ‘Drug addiction and HIV 
risks in the 2000 era’ organized by 
the Instituto Superiore di Sanitá
Policy makers, 
experts
6 April Edinburgh Workshop on the Problem Drug Use 
and Infectious Diseases Indicators
Experts
10–14 April Oeiras Advanced course on «Epidemiology of 
Infectious Diseases» organized by the 
Instituto Gulbenkian de Ciência
Experts
21 April Lisbon Visit of Centro Universitário Feevale de 
Novo Hamburgo (Brasil), Lisbon, 21 
April 2006.
Experts
30 May Lisbon Visit of Turkish national focal point Experts
22 September Lisbon Visit to the EMCDDA of the Federal 
Drugs Control Service of the Russian 
Federation
Policy makers, 
experts
2–3 October Stockholm ECDC Expert meeting on HIV 
prevention
Experts
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10–11 
October 
Lisbon EU expert meeting on the EMCDDA 
key indicator Drug-related Infectious 
Diseases
Experts
22–23 
November
Brussels 7th meeting of the “HIV/AIDS Think 
tank”
Policy makers, 
experts
Problem drug uses
21 April Lisbon Visit of Centro Universitário Feevale de 
Novo Hamburgo (Brasil), Lisbon, 21 
April 2006.
Experts
29 June Lisbon EMCDDA expert meeting on 
Environmental Prevention
Experts
22 September Lisbon Visit to the EMCDDA of the Federal 
Drugs Control Service of the Russian 
Federation
Policy makers, 
experts
12–13 
October
Lisbon EU expert meeting on the EMCDDA 
key indicator Problem Drug Use
Experts
24–25 
October
Paris Congrès annuel de la Société française 
de toxicologie 
Experts
5 December Lisbon Seminar on DG Research 7th research 
framework programme, EMCDDA
Experts
Action on new drugs
27–29 March Geneva Expert Committee on drug Dependence 
WHO 
Meeting with Swissmedic 
Experts
12 April Lisbon EMCDDA – WHO expert meeting ‘The 
functioning of the Expert committee of 
drug dependence (ECDD) of the UN 
system and the legitimate access to 
controlled medicines.’
Experts 
5 May Lisbon Technical meeting to review the draft 
EWS Operating Guidelines
Experts
15–16 June Lisbon 6th Annual meeting of the Reitox EWS 
correspondents
Experts
5–9 July Sofia Technical Seminar on the establishment 
of National Early Warning System on 
New Drugs
Experts
9–10 
October
Milan National Conference Monitoraggio 
Droghe e Manifestazioni di Abuso 
(M.D.M.A.) - Drug and Substance 
Abuse Monitoring
Experts
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12–15 
October
Larnaca Third Conference of the Euro 
Mediterranean Partnership against 
Substance Abuse (EMPASA) on 
Drug Policy – Balance between drug 
demand reduction and Drug Supply 
Reduction Measures
Experts
7 November Amsterdam Technical meeting on the revision of the 
Risk Assessment Guidelines
Experts
13–15 
November
Strasbourg 24th meeting of the Monitoring Group 
of the Anti-Doping Convention
Experts
28 November Lisbon Information exchange on new drugs: 
EMCDDA – Japanese Ministry of 
Health, Labour and Welfare (MHLW)
Experts
4–5 
December
Lisbon Technical meeting on the revision of the 
Guidelines for Risk Assessment of New 
Psychoactive Substances 
Experts, Scientific 
Committee
4–5 
December
Lisbon Support to 24th and 25th regular 
meetings of the meeting Scientific 
Committee 
Scientific 
Committee
Other meetings
10–15 March Porto Working group on Spatial analysis 
and geocoding of health data 
- Identification of problems and 
potentials
Experts
22–26 March Porto Working group on spatial analysis 
and geocoding of health data 
- Identification of problems and 
potentials
Experts
28 May–4 
June
Maastricht KBS Conference / 32nd Alcohol 
Epidemiology Symposium
Scientists
1–2 June Sofia Development of a survey training in 
recreational setting
Experts
20-21 June Porto 2nd Symposium on Neurobiology and 
Drug Abuse
Scientists
10 July Reggio Emilia Meeting on a Research project on drug 
at local level
Policy makers
7–11 August Rotterdam Training on “Principles of research 
in Medicine and Epidemiology/
Introduction to Data Analysis”
Experts
14–21 
October
Bucharest Training to the Romanian Focal Point 
on databases
Experts at NFP
13–14 
November
Köln Kick-off meeting Drug RUID Experts
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Programme RES – Monitoring the responses, law and policies – general
26 January Brussels Civil Society and Drugs in Europe NGO, experts
02 February Brussels Evaluation of the Action Plan 2005-
2008
Policy makers
10 March Paris Scientific Committee MILDT Experts
12 April Sofia Annual Conference of the National 
Centre for Addictions
Experts
15 May Paris Preparatory meeting of the 51st Iéna 
Forum
Policy makers, 
experts
16 May Geneva 
(Versoix)
Tasks Force meeting for Prison and 
Health
Policy makers, 
experts
7 June Brussels Meeting with the EC Policy makers
18-22 June Zagreb Re-assessment mission in Croatia Policy makers
17 July Luxembourg 7th Meeting coordination group 
(DG Sanco) - Final Meeting of the 
Coordination Group of Tender Sanco/
C4/2004/01 – DG Sanco
Policy makers, 
Commission, 
consultants
26 September Pula Croatian conference on drugs Experts and 
NGOs
11–12 
October
Paris Meeting with Jean-Michel Costes Experts
13–14 
November
Warsaw The EU-Russia Expert Meeting on Drugs 
and Drug Addiction
Policy makers
15–16 
November
Luxembourg Sanco C4 – technical meeting Policy makers, 
experts
16 November Luxembourg Meeting with Sanco Policy makers, 
experts
Prevention
17 November Bordeaux Conference at the University of 
Bordeaux
Experts
23 March Cáceres XXXIII Jornadas Nacionales de 
Socidrogalcohol
Experts, policy 
makers
13 January Brussels Collège Médical Interinstitutionnel Experts
10–11 
February
Padova-
Valência
International Prevention Conference, 
VIII-Reunión Nacional de 
Drogodependencias
Experts, policy 
makers
20–22 March Zagreb Pompidou-Group: Prevention among 
children of Drug users
Experts, policy 
makers
30 March Milan Re-Ligo, Convegno nazionale Experts, policy 
makers
17–18 May Ravensburg Congress ‘Grenzenlos dicht…?!’ Experts
31 May San Antonio 14th Annual Meeting Society of 
Prevention Research
Experts
22-25 June Brussels Dutch-German interregio project 
on Early Intervention and Self-Help 
(Alcohol and Cannabis)
Policy makers, 
professionals
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29–30 June Lisbon Expert Meeting on environmental 
strategies 
Experts
20–22 
September
Piran Club Health 2006 Experts, 
professionals
27 September Santiago de 
Compostela
Formación continua en prevención do 
consumo de alcohol e outras drogas
Experts, 
professionals
5–8 October Santiago de 
Compostela
BA-MI-GA Meeting: Needs, Chances 
and Challenges’ – Moving forward in 
Prevention
Policy makers
23 November Brussels ‘Europa e Tossicodipendenze’ Policy makers
24 November Coimbra Seminar ‘Famílias – Novas estratégias 
Preventivas’
Policy makers, 
professionals
29 
November–1 
December
Santa Cruz 40th Regular Session CICAD Policy makers
Harm reduction
16–17 
January
Luxembourg Green paper on Mental health 
Consultation – 1st thematic Meeting 
Group ‘Dialogue with member states’
Experts, NGOs, 
policy makers
20 January Porto Seminar ‘Bioética e Comportamentos 
Aditivos. As Salas de Injecção 
Assistida’
Experts, 
professionals, 
policy makers
30–31 
January
Barcelona Correlation Expert Group: Data report 
system
Experts
16–18 March Krakow 2nd Expert meeting of the Correlation 
Network
Network members: 
NGOs, public 
bodies
23 February Brussels 5th meeting Coordination Group 
Sanco Project
Commission, 
consultants
05–7 July Dublin Correlation EMCDDA Expert Group: 
Data report System
Experts
12 July Luxembourg 1st Meeting of Evaluation Committee 
DG Sanco Tender ‘Drugs Policy and 
Harm Reduction’
Commission
12–13 
October
Torino International conference ‘La riduzione 
del danno in Europa e in Italia’
Experts, 
professionals, 
policy makers
17 November Lisbon Information of staff of Drug Services 
Coordination of the City Council of 
Lisbon about European report on Drug 
Consumption Rooms
Experts
18 December Luxembourg Kick-off Meeting DG Sanco Tender 
‘Drug Policy and Harm Reduction’
Commission, 
consultants
19 December Caxias Visit to prison hospital – Dr Rui 
Andrade
Prison health staff
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Treatment and social rehabilitation
23–26 
March
Cologne Symposium: Heroin-assisted 
treatment – an innovative element of 
the Drug Support System
Experts, 
researchers
9–10 May Lisbon International Seminar on Drugs and 
Public Health in Prison
International and 
national experts, 
professionals, 
policy makers
27–30 
September
Porto VIII ISAM Meeting International 
experts
26–28 
October
Sinaia Conference on Prison and public 
Health and Annual Meeting of WHO 
European Network for Prison and 
Health
HIPP Network 
members, WHO, 
Romanian national 
experts
EDDRA and science based practices
26 February–
3 March
Antigua Taller sobre consejeria y tratamiento 
del consume de drogas en los centros 
penitenciarios
Experts
9–11 July Santander Sistemas de Evaluación en las 
Intervenciones en Drogodependencias
Experts
3–4 October Lisbon EDDRA Managers meeting Experts
24 November Venice Regional Prevention action meeting Experts
National and community strategies
30 October Paris OFDT: study on cocaine users Experts
04 December London Drug Policy Seminar – UNGASS and 
the Contribution of Civil Society
NGOs
National drug strategies
16–17 
February
Innsbruck National Drug Coordinators Meeting 
– Austrian Presidency
Policy makers, 
experts
23 February Brussels EULAC Meeting Policy makers, 
experts
24 February Brussels Horizontal Drugs Group meeting Policy makers, 
experts
2 March Brussels Evaluation of the Action Plan 2005-
2008
Policy makers, 
experts
6–7 March Vienna EULAC Drugs Meeting Policy makers, 
experts
6 March Brussels Meeting on ‘Fiche Drogue’ Policy makers, 
experts
7 March Brussels Horizontal Drugs Group meeting Policy makers, 
experts
11–12 May Brussels EU Drugs Troika Policy makers, 
experts
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7 June Brussels Horizontal Drugs Group meeting Policy makers, 
experts
8 June Brussels EULAC meeting Policy makers, 
experts
9 June Brussels EU/US informal dialogue meeting Policy makers, 
experts
26–27 June Moscow Ministerial Conference on Drug 
trafficking routes from Afghanistan
Policy makers, 
experts
6–7 July Luxembourg 7th Meeting of the network for Health 
Promotion and Knowledge
Policy makers, 
experts
27 September Brussels EU Andean High Level Meeting Policy makers, 
experts
25 October Brussels Meeting of the Evaluation Committee of 
the external evaluation of the EMCDDA
Policy makers, 
experts
30 October Brussels EU Drugs Troika with Russia Policy makers, 
experts
31 October Brussels Horizontal Drugs Group meeting Policy makers, 
experts
6–7 
November
Bern Informal Drug Policy Dialogue Policy makers, 
experts
16 November Bilbao Symposium ‘Hablemos del Cannabis’ Policy makers, 
experts
01 December Brussels Evaluation meeting: Methodological 
study on the impact of the AP
Policy makers, 
experts
30 May–02 
June
Vienna EU-Workshop Drug Policy Balkan Policy makers, 
experts
21–22 June Paris 51ième Forum d’Iéna Policy makers
09–11 July Strasbourg Pompidou-Group: Road Traffic and 
Drugs seminar
Policy makers, 
experts, 
professionals
28–29 
September
Brussels Inter-service group + HDG Policy makers and 
experts
14 October Palmela EWDTS Board meeting Policy makers, 
experts
16–18 
October
Paris Pompidou-Group: Platform on Ethics Experts
19–20 
October
Paris Eurogip debate Experts, 
professionals
24–27 
October
Brussels Improving Operational Cooperation 
– OLAF
Professionals, 
experts
2 October Lisbon 7th Meeting of the Legal 
Correspondents
Policy makers, 
experts
16 November Lisbon Meeting on Implementation of Drug 
Laws
Policy makers, 
experts
General report of activities 2006
98
Reitox and international cooperation 
6–7 March Vienna High-level meeting of the EU-LAC 
mechanism for drugs cooperation and 
coordination
Policy makers
20–21 April Lisbon National Reitox Academy (IDT) Experts FP
31 July–4 
August
Paris National Reitox Academy (OFDT) Experts FP
29–30 June Larnaca Reitox Academy on grant agreements Experts FP
19–22 
September 
Rio de 
Janeiro
Interpol General Assembly Policy makers, 
experts
6 October Lisbon European Union agencies meeting on 
Enlargement of data collection and 
networks to third countries
EU agencies
29 October–
4 November 
Washington Meeting with CICAD Policy makers
6 December Kiev Opening of the Ukrainian Drug 
Monitoring Centre
Policy makers, FP
Scientific coordination unit
16–18 
January
Helsinki 2nd Workshop Network for European 
Research in Drug use and Addiction 
(NERUDA)
Experts
20 March Bilbao European Agency for Safety and 
Health at Work (OSHA) 10th 
Anniversary
EU agency
23–25 March Cologne Federal Ministry for Health Experts, 
professionals
30–31 March Paris Heroin assisted treatment symposium 
Pompidou Group Platform on Ethics
Policy makers and 
experts
6–7 April Gdansk Pompidou Group 4th Research Platform Policy makers and 
experts
24–26 April Prague UNODC/European Centre for Social 
Welfare Policy and Research 
Multi city study on quantities and 
financing of illicit drug consumption 
– ‘QUAF’
Policy makers, 
experts, 
professionals
25–26 May Dresden 2nd Meeting of the German Addiction 
Research Network 
Understanding Addiction: Mediators 
and Moderators of Behaviour Change 
Processes
Experts
30 August–1 
September
Helsinki International Society of Addiction 
Journal Editors (ISAJE), yearly 
Conference
Experts
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21–23 
September
Lisbon European Society for Social Drug 
Research (ESDD), 17th Annual 
Conference
Policy makers, 
experts, 
professionals
16–17 
October
Bremen ELISAD Gateway Project 2005–2007 
Workshop
Experts
23 November Bucharest Launch of EMCDDA Annual Report 
2006
Policy makers
Public expenditure and costs
23–25 
October
Prague Meeting with Thomas Zabránsky Experts
3–4 
November
Berlin Kongress der Deutsche Gesellschaft für 
Suchmedizin. Berlin.
Professionals
27–28 
November
Lisbon EMCDDA Expert Meeting on 
Methodology and Use of Cost of Illness 
Results in Drugs Field in the European 
Union
Experts and 
interested NFPs 
delegates
Annexes
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Annex 4 
Members of the EMCDDA’s statutory bodies
Members of the Management Board
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Members of the Scientific Committee
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Members of the Scientific Committee (continued)
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2006 budget appropriations and execution by 
nature of expenditure
Financial and accounting management 
A budget of € 13 015 625 was adopted for the implementation 
of the 2006 work programme. The budgetary figures for 2006 are 
presented in the tables below. 
Budgetary provisions and appropriations, 2006
Annexes
Execution of the budget: credit consumption, 2006 (commitments)
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Balance sheet at 31 December 2006 — Assets
31.12.2005
-924 767.69
-738 465.01
107
Balance sheet at 31 December 2006 — Liabilities
Accrued charges
Deferrals and accruals with
31.12.2005
Annexes
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Budget out-turn account 2006: revenue and expenditure
Commission subsidy (for the operating budget - titles
1, 2 and 3 - of the agency)
Phare funds from the Commission
Other funding and contributions received via the
Commission
Other donors
Other revenue
Fee income
109
Negotiated procedures launched in 2006 
European Monitoring Centre for Drugs and Drug Addiction, 2007
General report of activities 2006
Lisbon: European Monitoring Centre for Drugs and Drug Addiction
2007 — 110 pp. — 21 x 29.7 cm
Language: EN 
Catalogue Number: TD-AB-07-001-EN-N 
ISSN: 1725-4558
Annexes
6 54 193 19 166 758 25 76% 220 950 54%
4 115 038 4 70 321 8 24% 185 359 46%
10 169 230 23 237 079 33 100% 406 309 100%
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